Regulatory molecule for enhancing killing effect of CD8 + t cells and use thereof
By regulating the MondoA-TXNIP axis, the killing effect of CD8+ T cells is enhanced, which solves the problem of poor killing effect of CD8+ T cells against tumors and pathogens, especially the therapeutic effect on tumors resistant to immune checkpoint inhibitors. It improves the cytotoxicity and cytokine release of CD8+ T cells and weakens the inhibitory effect of Treg cells.
Patent Information
- Application Number
- PCT/CN2026/089563
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-04-09
- Publication Date
- 2026-11-12
AI Technical Summary
Current technologies have not effectively addressed the killing effect of CD8+ T cells in tumors and pathogen infections, especially in treating tumors resistant to immune checkpoint inhibitors, and the inhibitory effect of Treg cells on CD8+ T cells has not been effectively alleviated.
By regulating the MondoA-TXNIP axis, including knocking out, knocking down, or silencing the MondoA and TXNIP genes, and using small molecule compounds to inhibit their activity, the killing effect of CD8+ T cells is enhanced, the inhibitory effect of Treg cells is weakened, cytokine release and glycolytic metabolism are promoted, and their ability to kill tumors and pathogens is enhanced.
It enhanced the killing ability of CD8+ T cells against tumors and pathogens, especially the therapeutic effect on tumors resistant to immune checkpoint inhibitors, increased the cytotoxicity and cytokine release of CD8+ T cells, and weakened the inhibitory effect of Treg cells.
Smart Images

Figure PCTCN2026089563-FTAPPB-I100001 
Figure PCTCN2026089563-FTAPPB-I100002 
Figure 00000030_0000
Abstract
Description
Enhanced CD8 + Regulatory molecules of T cell killing and their applications
[0001] This patent application claims priority to patent application No. CN 202510604221.8, filed on May 9, 2025, the entire contents of which are incorporated herein by reference. Technical Field
[0002] This invention belongs to the field of biomedicine, and more specifically, this invention relates to a method for enhancing CD8. + Regulatory molecules of T cell killing and their applications. Background Technology
[0003] The functions of the body's immune system are to protect the body from external pathogens, maintain the stability of the internal environment, and prevent the occurrence of tumors. These functions together constitute an important line of defense for the body's immune system, providing strong protection for the body's health.
[0004] The immune system is a complex network of cells, tissues, and molecules, comprising innate (non-specific) immunity and adaptive (specific) immunity. T lymphocytes originate in the bone marrow, mature in the thymus, proliferate, and differentiate into effector cells and memory cells with different functions. They migrate from the blood to peripheral lymphoid tissues and are distributed throughout almost every organ and tissue in the body, playing a crucial role in cellular immunity. T cells are one of the main cellular components of the immune system.
[0005] Different types of T cells have significantly different functions. Some major T cells include: CD4+ + Helper T cells (CD4) + T cells), CD8 + Killer T cells (CD8) + T cells, regulatory T cells (Treg cells).
[0006] CD4 + Helper T cells recognize MHC class II antigens to coordinate immune responses and indirectly help clear extracellular pathogens by secreting cytokines such as IL-2 and IFN-γ that enhance phagocytes and other T cells; CD4 + T cells exhibit significant heterogeneity in secreting cytokines, possess specific pro-inflammatory or anti-inflammatory properties, and contribute to adaptive immune responses.
[0007] CD8 + Killer T cells recognize antigenic peptides presented by MHC-I molecules and initiate a “suicide program” for target cells, directly killing cells infected by pathogens and tumor cells. Different subgroups exhibit unique phenotypic and functional characteristics, enabling them to play specific roles in various immune environments.
[0008] Treg cells are regulatory T cells with immunosuppressive effects, which exert their effector function by inhibiting CD4+. + T cell subsets and CD8 + The overactivation, proliferation, and differentiation of T cells maintain the stability of the immune system and participate in the regulation of diseases such as autoimmune diseases, allergic reactions, organ transplantation, tumors, and inflammatory responses.
[0009] Therefore, different types of immune cells differ significantly in function, and even the same protein molecules can play significantly different regulatory roles in different types of immune cells. Further research is needed in this field to optimize immune cell function and provide more pathways for the prevention and mitigation of diseases based on the immune system. Summary of the Invention
[0010] The purpose of this invention is to provide an enhanced CD8 + Regulatory molecules of T cell killing and their applications.
[0011] In a first aspect of the invention, a downregulating molecule of the MondoA-TXNIP axis is provided for the preparation of enhanced CD8 + Use in formulations that induce T-cell killing.
[0012] In one or more embodiments, the MondoA-TXNIP axis includes: MondoA (gene / protein), TXNIP (gene / protein), which interact with each other; preferably, it also includes their upstream and downstream regulatory genes / proteins or chemical molecules.
[0013] In one or more embodiments, the TXNIP also includes its homolog ARRDC4.
[0014] In one or more embodiments, the MondoA-TXNIP axis is a signaling pathway in immune cells.
[0015] In one or more embodiments, the downregulated molecule includes a selection from: MondoA downregulated molecules, TXNIP downregulated molecules, and downregulated molecules in which MondoA interacts with TXNIP (MondoA protein binds to the TXNIP gene promoter and promotes TXNIP expression).
[0016] In one or more embodiments, the MondoA downregulating molecule includes (but is not limited to): agents that knock out, knock down, or silence the MondoA gene or the TXNIP gene; agents that inhibit the activity of the MondoA protein or the TXNIP protein; more preferably, the MondoA downregulating molecule includes (but is not limited to): small molecule compounds that specifically inhibit the activity of the MondoA protein or the TXNIP protein; CRISPR gene editing agents (such as sgRNA), homologous recombination agents, or site-directed mutagenesis agents targeting the MondoA gene or the TXNIP gene, said agents causing loss-of-function mutations in the MondoA gene or the TXNIP gene; interfering molecules (such as siRNA, shRNA, miRNA, antisense nucleotides, etc.) that specifically interfere with the expression of the MondoA gene or the TXNIP gene; more preferably, the small molecule compound that specifically inhibits the MondoA protein includes: SBI-477.
[0017] In one or more embodiments, the downregulating molecules of the MondoA-TXNIP interaction include (but are not limited to): agents that weaken the binding of MondoA to the TXNIP gene promoter.
[0018] In one or more embodiments, the enhanced CD8 + T-cell killing effects include: tumor suppression; preferably, the tumor includes tumors resistant to immune checkpoint inhibitors (blockers); more preferably, the tumor includes (but is not limited to): colorectal cancer, pancreatic cancer, melanoma; more preferably, the immune checkpoint inhibitor includes: anti-PD-1, anti-PD-L1, or anti-CTLA4.
[0019] In one or more embodiments, the enhanced CD8 + T-cell killing functions include: inhibiting pathogens, such as viruses or bacteria.
[0020] In one or more embodiments, the enhanced CD8 + T-cell killing effects include: enhancing CD8+. + T cell cytotoxicity (including cytotoxic / killing effects on pathogens such as viruses or bacteria, tumor cells, etc.).
[0021] In one or more embodiments, the enhanced CD8 + T-cell killing effects include: promoting CD8+ + T cells produce cytokines; preferably, the cytokines include: IFN-γ, TNF-α, GZMB, and Perforin.
[0022] In one or more embodiments, the downregulated molecule weakens the effect of Treg cells on CD8. + Suppressive effect of T cells.
[0023] In one or more embodiments, downregulating MondoA can enhance CD8. + It enhances the glycolytic metabolism and mitochondrial function of T cells, thereby increasing their cytotoxic effects.
[0024] In another aspect of the invention, the MondoA-TXNIP axis is provided for use in screening enhanced CD8. + Substances that induce T-cell killing.
[0025] In another aspect of the invention, a screening enhancement CD8 is provided. + A method for detecting substances that induce T-cell killing includes: (1) contacting a candidate substance with a system containing the MondoA-TXNIP axis; and (2) screening for substances that downregulate the MondoA-TXNIP axis, said substance being effective against CD8+. + Substances useful for T-cell killing (including potential substances); wherein the downregulation includes: downregulating MondoA, downregulating TXNIP, or downregulating the interaction between MondoA and TXNIP.
[0026] In one or more embodiments, step (1) includes adding a candidate substance to a system containing the MondoA-TXNIP axis; step (2) includes detecting changes in each protein or its encoding gene in the MondoA-TXNIP axis and comparing it with a control group, wherein the control group is a system containing the MondoA-TXNIP axis without the addition of the candidate substance; if the candidate substance downregulates MondoA, downregulates TXNIP, or downregulates the interaction between MondoA and TXNIP (inhibiting MondoA protein binding to the TXNIP gene promoter, inhibiting TXNIP expression), then the candidate substance is effective in enhancing CD8 expression. + Substances useful for T-cell killing.
[0027] In one or more embodiments, the system containing the MondoA-TXNIP axis is selected from: cell (culture) systems, subcellular (culture) systems, tissue (culture) systems, or animal systems.
[0028] In one or more embodiments, the downregulation may also be referred to as inhibition, reduction, weakening, or blocking, and is a statistical downregulation, such as a downregulation of 10% or 20% or more compared with the control or baseline, preferably inhibiting or downregulating by 40% or 50% or more, and more preferably inhibiting or downregulating by 80% or 100% or more.
[0029] In one or more embodiments, the candidate substances include (but are not limited to): regulatory molecules (such as, but not limited to, upregulators, interfering molecules, nucleic acid inhibitors, binding molecules (such as antibodies or ligands)) designed to target the MondoA-TXNIP axis, or its pathway proteins, or its upstream or downstream proteins or genes; CRISPR constructs; small molecule compounds; and compounds from a compound library.
[0030] In another aspect of the invention, a modified CD8 is provided. + T cells (or CD8) + T cell cultures, wherein the cells have enhanced killing activity (e.g., killing of pathogens / tumors), wherein an exogenous MondoA-TXNIP axis downregulating molecule is introduced, or the cells are treated with an exogenous MondoA-TXNIP axis downregulating molecule; the downregulating molecule includes a selection from: MondoA downregulating molecules, TXNIP downregulating molecules, and downregulating molecules that interact with MondoA and TXNIP (MondoA protein binds to the TXNIP gene promoter, promoting TXNIP expression); the downregulating molecule is the downregulating molecule defined above.
[0031] In another aspect of the invention, the modified CD8 is provided. + T cells (or CD8) + The application of T-cell cultures for the preparation of agents or kits that inhibit tumors or pathogens (such as viruses or bacteria); preferably, the tumors include tumors resistant to immune checkpoint inhibitors (blockers); more preferably, the tumors include (but are not limited to): colorectal cancer, pancreatic cancer, melanoma; preferably, the immune checkpoint inhibitors include: anti-PD-1, anti-PD-L1, or anti-CTLA4.
[0032] In another aspect of the invention, an agent or kit for inhibiting tumors or pathogens (such as viruses or bacteria) is provided, comprising the modified CD8. + T cells (or CD8) + T-cell culture); preferably, the formulation also includes a pharmaceutically acceptable carrier.
[0033] In another aspect of the invention, an enhanced CD8 is provided. +Preparations or kits containing T-cell killing / tumor-inhibiting or pathogen-inhibiting agents, wherein the preparation comprises an effective amount of a MondoA-TXNIP axis downregulating molecule and an immune checkpoint inhibitor (blocker). Preferably, the downregulating molecule comprises a selection from: MondoA downregulating molecules, TXNIP downregulating molecules, and downregulating molecules that interact with MondoA and TXNIP (MondoA protein binds to the TXNIP gene promoter, promoting TXNIP expression), such as the small molecule compound SBI-477 that specifically inhibits MondoA activity; preferably, the immune checkpoint inhibitor (blocker) comprises: anti-PD-1, anti-PD-L1, or anti-CTLA4.
[0034] In another aspect of the invention, the use of a reagent that specifically recognizes proteins or their encoding genes in the MondoA-TXNIP axis is provided for the preparation of a reagent for CD8. + Reagents or kits for analyzing T-cell killing activity; preferably, the analysis includes: determining the killing activity based on the expression of MondoA and / or TXNIP, or determining whether a subject is suitable for a treatment regimen that uses "downregulated molecules along the MondoA-TXNIP axis"; if MondoA and / or TXNIP are highly expressed, then the treatment regimen is applicable.
[0035] In another preferred embodiment, the diagnostic reagent comprises primers selected from: primers that specifically amplify the coding genes of MondoA and / or TXNIP proteins; probes that specifically recognize the coding genes of MondoA and / or TXNIP proteins or their transcripts; or antibodies that specifically target MondoA and / or TXNIP proteins.
[0036] In another aspect of the invention, a method for CD8 is provided. + A kit for analyzing T-cell killing activity, wherein the kit contains: diagnostic reagents for detecting the expression or expression level of MondoA and / or TXNIP proteins or their encoding genes.
[0037] In another preferred embodiment, the kit further includes: nucleic acid extraction reagent, polymerase chain reaction reagent, Western blotting reagent, and / or enzyme-linked immunosorbent assay (ELISA) reagent.
[0038] Other aspects of the invention will be apparent to those skilled in the art from the disclosure herein. Attached Figure Description
[0039] Figure 1. Lactic acid upregulates Treg and CD8 + TXNIP and ARRDC4 expression on T cells.
[0040] (A) Separation of CD4 from peripheral blood of healthy individuals + T cells and CD8 + T cells, CD4 + T cell-induced iTreg cells were generated, and iTreg cells and CD8 were treated with 10mM lactate in vitro. + Twenty-four hours after T cell administration, RNA-seq analysis was performed. Venn diagrams showed the effects of lactate treatment on iTregs and CD8. + Common differentially expressed genes in two sets of RNA-seq data of T cells.
[0041] (BC) Volcano plot shows lactic acid treatment CD8 + Differentially expressed genes in T cells (B) and iTreg cells (C).
[0042] (DE) Heatmap shows CD8 + The top 20 genes differentially expressed in T cells (D) and iTreg cells (E) between the control group and the lactate treatment group (Padj<0.05).
[0043] (FG) CD8 cells were treated in vitro with 10 mM lactate. + Gene expression was detected by RT-qPCR 24 hours after T cells (F) and iTreg cells (G) were collected (n=3).
[0044] (HI) CD8 cells were treated in vitro with 10 mM lactate. + T cells and iTreg cells were detected by Western blot 24 hours later. + Expression of TXNIP in T cells (H) and iTreg cells (I).
[0045] (J) Isolation of CD8 from human peripheral blood + T cells were treated with 10mM lactate in vitro for 24 hours, and CD8 was detected by RT-qPCR. + Expression of genes related to T cell cytotoxic function (n=3).
[0046] (K) CD4 groups were isolated from peripheral blood of healthy individuals. + T cells were used to induce iTreg cells, which were then treated with 10 mM lactate in vitro for 24 hours. The expression of genes related to inhibitory function in iTreg cells was detected by RT-qPCR (n=3).
[0047] (L) Sorting Treg cells from WT mice and mixing them with Cell Trace Violet-labeled wild-type CD8+ cells at the appropriate ratio. +T cells were mixed, stimulated with anti-CD3 / CD28 magnetic beads, and cultured for 3 days. They were then treated in vitro with 5mM lactate or a control for 24 hours, and CD8+ was detected by flow cytometry. + The proliferation of T cells was analyzed and statistically analyzed (n=3-4).
[0048] Data are expressed as mean ± SEM. Sidak multiple comparison tests using two-way ANOVA were applied to F, G, J, K, and L.
[0049] Figure 2. Lactic acid upregulates Treg and CD8 + TXNIP and ARRDC4 expression on T cells.
[0050] (AB) Volcano plot shows lactic acid treatment CD8 + Differentially expressed genes in T cells (A) and Treg cells (B).
[0051] (CD) CD8 is isolated from peripheral blood of healthy individuals. + T cells were treated in vitro with 10 mM sodium lactate, 10 mM lactate, or a control group for 24 hours. TXNIP levels were analyzed by RT-qPCR (C) and Western blot (D).
[0052] Data are expressed as mean ± SEM. A two-tailed t-test is applied in C.
[0053] Figure 3. MondoA-TXNIP axis in lactate-induced CD8 + T cells play an important role in T cell dysfunction.
[0054] (AB) CD8 was isolated from peripheral blood of healthy individuals. + T cells, after being pretreated with 10mM lactate for 24 hours in vitro, CD8 + T cells were co-incubated with 2-NBDG for 30 minutes, and the intracellular fluorescence intensity was detected by flow cytometry.
[0055] (CD) Immunofluorescence shows CD8 cells treated with lactate or the control group. + Subcellular localization and statistical results of MondoA in T cells (MondoA (red), DAPI (blue), scale bar, 7.5 μm)
[0056] (E) CD8 cells were treated in vitro with 10 mM lactate or as a control group. + T cells were used to detect the enrichment of MondoA on the TXNIP and ARRDC4 promoters by ChIP-qPCR after 24 hours.
[0057] (FG) Stimulation of CD8 with anti-CD3 / CD28 antibody +T cells were treated with 10 μM SBI-477 for 24 hours. + T cells were analyzed for MondoA and TXNIP expression 24 hours later using RT-qPCR (F) and western blot (G).
[0058] (HI) Stimulation of CD8 with anti-CD3 / CD28 antibody + T cells were treated with 10 μM SBI-477 for 24 hours. + T cells were used to detect the enrichment of MondoA on the TXNIP(H) and ARRDC4(I) promoters by ChIP-qPCR after 24 hours.
[0059] (JK)CD8 + T cells were treated with 10 mM lactate, 10 μM SBI-477, or lactate plus SBI-477 for 24 hours, and CD8 were detected by flow cytometry. + IFN-γ levels in T cells.
[0060] (LM)CD8 + T cells were treated with 10 mM lactate, 10 μM SBI-477, or lactate plus SBI-477 for 24 hours, and CD8 were detected by flow cytometry. + TNF-α levels in T cells.
[0061] Data are expressed as mean ± SEM. Two-tailed t-tests were applied in B and D. Sidak's multiple comparison test using two-way ANOVA was applied in E, F, H, and I. Tukey's multiple comparison test using one-way ANOVA was applied in K and M.
[0062] Figure 4. MondoA knockout enhances in vivo tumor-infiltrating CD8. + T-cell anti-tumor immunity.
[0063] (AB)MondoA fl / fl (6) and MondoA fl / fl Seven Cd4-Cre mice were subcutaneously injected with MC38 colorectal cancer cells. The size (A) and weight (B) of the tumors in the mice were recorded.
[0064] (C) Quantitative analysis of MondoA fl / fl (n=5) and MondoA fl / fl Cd4-Cre (n=8) mice with tumor-infiltrating CD4+ + T cells and CD8 + T cell count.
[0065] (DE) Flow cytometry detection (D) and quantitative analysis (E) MondoA fl / fl(n=5) and MondoA fl / fl Cd4-Cre (n=6) mice with tumor-infiltrating CD4+ + T cells and CD8 + Expression of IFN-γ in T cells.
[0066] (FG) from MondoA fl / fl OTI (5 pieces) and MondoA fl / fl CD86 was sorted by flow cytometry in 5 Cd4-Cre OTI mice. + T cells will sort CD8 + T cells were adopted into CD45.1 mice that were subcutaneously injected with MC38-OVA cells, and the size (F) and weight (G) of the tumors in the CD45.1 mice were recorded.
[0067] (HI) Flow cytometry detection (H) and quantitative analysis (I) of CD8 infiltrating mouse tumors + The ratio of IFN-γ and TNF-α secreted by T cells (n = 3-4).
[0068] (J) The concentration of lactate in the culture medium of MC38 colorectal cancer cells transfected with shNC or shLdha.
[0069] (K) Lactate concentration in culture medium 24 hours after MC38 colorectal cancer cells were treated with control or 10 mM LDHA inhibitor oxamate.
[0070] (L) shNC-transfected MC38 colorectal cancer cells were treated with a control or oxamate, and shLdha-transfected MC38 colorectal cancer cells were compared with MondoA. fl / fl mouse CD8 + T cells were treated with control or SBI-477, and MondoA. fl / fl CD8 in Cd4-Cre mice + T cell co-culture, CD8 analysis + T cell cytotoxicity (n=3).
[0071] (M) Transfect control shNC with LDHA high ) or shLdha transfection (LDHA) low MC38 colorectal cancer cells were subcutaneously injected into MondoA fl / fl (n=6) or MondoA fl / fl In Cd4-Cre (n=5) mice, the weight of the tumors in the mice was counted.
[0072] (N) Flow cytometry detection and quantitative analysis of subcutaneously injected LDHA high or LDHAlow MondoA of MC38 colorectal cancer cells fl / fl And MondoA fl / fl CD8+ tumor-infiltrating mice + IFN-γ and TNF-α (n=6) produced by T cells.
[0073] Data are expressed as mean ± SEM. Two-tailed t-tests were applied in B, G, J, and K. Sidak's multiple comparison test using two-way ANOVA was applied in A, C, E, F, I, M, and N, and Tukey's multiple comparison test using two-way ANOVA was applied in L.
[0074] Figure 5. Effect of T cell knockout of MondoA.
[0075] (AB) From 8 weeks of age MondoA fl / fl And MondoA fl / fl CD8 was isolated from Cd4-Cre mice + T cells were used to detect the expression of MondoA and TXNIP by RT-qPCR and Western blot.
[0076] Data are expressed as mean ± SEM. Sidak's multiple comparison test using two-way ANOVA is applied in A.
[0077] Figure 6. MondoA deficiency does not affect T cell homeostasis.
[0078] (AC) Flow cytometry detection of 8-week-old MondoA fl / fl And MondoA fl / fl CD4+ in the spleen, mesentery, and peripheral lymph nodes of Cd4-Cre mice + T cells (A), CD8 + The ratio of T cells (B) to Treg cells (C) (n = 4-5).
[0079] (DE) Flow cytometry detection of 8-week-old MondoA fl / fl And MondoA fl / fl CD4 in the thymus of Cd4-Cre mice - CD8 - (DN), CD4 - CD8 + (CD8 SP), CD4 + CD8 - (CD4 SP) and CD4 + CD8 + (DP) ratio (n=5).
[0080] (FG) Flow cytometry detection of 8-week-old MondoAfl / fl And MondoA fl / fl CD4+ in the spleen, mesentery, and peripheral lymph nodes of Cd4-Cre mice + T cells (F) and CD8 + CD62L in T cells (G) lo CD44 hi The expression (n = 4-5).
[0081] (HI) Flow cytometry detection of 8-week-old MondoA fl / fl And MondoA fl / fl CD4+ in the spleen, mesentery, and peripheral lymph nodes of Cd4-Cre mice + T cells (H) and CD8 + Expression of Ki-67 in T cells (I) (n=4-5).
[0082] (J) Flow cytometry detection of 8-week-old MondoA fl / fl And MondoA fl / fl CD8+ in the spleen, mesentery, and peripheral lymph nodes of Cd4-Cre mice + IFN-γ and TNF-α expression in T cells (n=3).
[0083] Data are expressed as mean ± SEM. The Sidak multiple comparison test using two-way ANOVA was applied in AJ.
[0084] Figure 7. Lactic acid and TCR / CD28 signaling coordination CD8 + Expression of TXNIP in T cells.
[0085] (A) Venn diagram analysis of two groups of differentially expressed genes. One group is lactate-treated CD8. + RNA-seq data of T cells; another set of data came from single-cell data of colorectal cancer patients, showing the relationship with resting CD8+. + Compared to T cells (Tn), effector memory (Tem) CD8 + Differential gene expression in T cells.
[0086] (B) CD8 infiltration of human colorectal tumors and normal colorectal tissue + Quantitative analysis of mean fluorescence intensity (MFI) of TXNIP in T cells (n=7).
[0087] (C) Violin diagram showing resting (Tn) and effective memory (Tem) CD8 + TXNIP levels in T cells (data from publicly available colorectal cancer tumor samples).
[0088] (DE) CD8 isolating from peripheral blood of healthy individuals+ T cells were stimulated with anti-CD3 / CD28 magnetic beads to target CD8 cells. + T cells were used to analyze TXNIP expression using RT-qPCR (D) and western blot (E).
[0089] (FH) Stimulating CD8 with anti-CD3 / CD28 magnetic beads + T cells, Seahorse analysis of CD8 + ECAR (F) of T cells and statistical glycolysis rate (G) and glycolytic capacity (H).
[0090] (IJ) Immunofluorescence showed CD8 activation at rest and with anti-CD3 / CD28 magnetic beads. + Subcellular localization of MondoA in T cells (J) (MondoA (red), DAPI (blue), scale bar, 7.5 μm) and Pearson correlation coefficient (n=10) analysis (I).
[0091] (K) Stimulating CD8 with anti-CD3 / CD28 magnetic beads + T cells 24 hours later, CD8 count was detected by ChIP-qPCR. + MondoA enrichment at the TXNIP promoter in T cells (n=3).
[0092] (L) CD8 groups were isolated from peripheral blood of healthy individuals. + T cells were treated with anti-CD3 / CD28 magnetic beads, anti-CD3 / CD28 magnetic beads with 10mM lactate, or a control group. + T cells were analyzed for TXNIP expression using RT-qPCR (n=3).
[0093] (MP) CD8 was isolated from peripheral blood of healthy individuals. + T cells were treated with anti-CD3 / CD28 magnetic beads, anti-CD3 / CD28 magnetic beads with 10mM lactate, or a control group. + T cells, flow cytometry detection (M, O) and quantitative analysis (N, P) of CD44 and Ki67 expression.
[0094] Data are expressed as mean ± SEM. Two-tailed t-tests were applied to B, D, G, H, I, L, N, and P. Sidak's multiple comparison test with two-way ANOVA was applied to K.
[0095] Figure 8. MondoA deletion enhancement CD8 + T-cell glycolytic metabolism and mitochondrial function.
[0096] (A)From MondoA fl / fl And MondoA fl / fl CD8 was isolated from Cd4-Cre mice + T cells were stimulated with anti-CD3 / CD28 antibodies in vitro for 24 hours, and RNA-seq was performed. Gene set enrichment (GSEA) analysis showed enrichment of genes associated with glycolysis metabolism.
[0097] (B) GSEA analysis compared CD8 deletions in WT and MondoA. + The enrichment of oxidative phosphorylation metabolism in the T cell transcriptome.
[0098] (C) From MondoA fl / fl (n=8) and MondoA fl / fl CD8 isolated from Cd4-Cre (n=5) mice + T cells were stimulated with anti-CD3 / CD28 antibody in vitro for 24 hours, and CD8 counts were detected and statistically analyzed by immunofluorescence. + The mean fluorescence intensity of GLUT1 in T cells was analyzed using ImageJ software.
[0099] (D) In vitro stimulation of CD8 with anti-CD3 / CD28 antibody + T cells 24 hours later, Seahorse analysis of CD8 + ECARs from T cells (n=4).
[0100] (E)GSEA analysis of lactic acid treatment CD8 + RNA-seq data from T cells showed enrichment of gene signatures associated with glycolytic metabolism.
[0101] (F)GSEA analysis of lactic acid treatment CD8 + RNA-seq data from T cells showed gene signatures enriched in oxidative phosphorylation metabolism.
[0102] (G) In vitro treatment of WT and MondoA-deficient CD8 cells with 10 mM lactate. + T cells 24 hours later, immunofluorescence detection and CD8 count + The mean fluorescence intensity of GLUT1 in T cells was analyzed using ImageJ software.
[0103] (H) In vitro stimulation of WT and MondoA-deficient CD8 cells with anti-CD3 / CD28 antibody. + T cells 24 hours later, Seahorse analysis of CD8 + Extracellular oxygen consumption (OCR) of T cells (n = 3-4).
[0104] (IJ) In vitro treatment of WT and MondoA-deficient CD8 cells with 10 mM lactate or control group. + T cells 24 hours, CD8 + T cells and MitoTracker TM Red CMXRos co-incubation, flow cytometry detection (I) and statistics (J) MitoTracker TM Fluorescence intensity of Red CMXRos (n=3).
[0105] (KN) In vitro treatment of WT and MondoA-deficient CD8 cells with 10 mM lactate or control group. + T cells were analyzed by electron microscopy at 24 hours to determine mitochondrial morphology (K) and quantitative mitochondrial number (L), cristae number (WT-Ctrl n=19, WT-LA n=26, KO-Ctrl n=34, KO-LA n=27) and width (Each group n=30) (MN).
[0106] Data are expressed as mean ± SEM. Two-tailed t-tests were applied in C, G, and LN. Sidak's multiple comparison test with two-way ANOVA was applied in J.
[0107] Figure 9. MondoA knockout enhances in vivo tumor infiltration CD8 + T-cell anti-tumor immunity.
[0108] (AB)MondoA fl / fl And MondoA fl / fl Subcutaneous injection of MC38 colorectal cancer cells into Cd4-Cre mice; flow cytometry detection (A) and quantitative analysis (B) of CD4+ in draining lymph nodes. + T cells and CD8 + The proportion of T cells (n=6).
[0109] (CE)MondoA fl / fl (n=6) and MondoA fl / fl Subcutaneous injection of MC38 colorectal cancer cells into Cd4-Cre (n=8) mice; flow cytometry detection (C) and quantitative analysis (DE) of CD4+ in draining lymph nodes. + T cells and CD8 + The levels of IFN-γ and TNF-α secreted by T cells.
[0110] (FG) Flow cytometry detection (F) and quantitative analysis (G) MondoA fl / fl OTI and MondoA fl / fl CD8 in the draining lymph nodes of Cd4-Cre OTI tumor-bearing mice +The levels of IFN-γ and TNF-α produced by T cells (n=4).
[0111] Data are expressed as mean ± SEM. Sidak multiple comparison tests using two-way ANOVA were applied in categories B, D, E, and G.
[0112] Figure 10. SBI-477 simultaneously promotes CD8 + T cell function and the inhibitory function of damaged Treg cells.
[0113] (AB) In vitro stimulation of CD8 with anti-CD3 / CD28 antibody + T cells were treated with SBI-477 for 24 hours after treatment. Flow cytometry was used to detect (A) and statistical analysis (B) the mean fluorescence intensity of 2-NBDG (n=3-4).
[0114] (C) From MondoA fl / fl And MondoA fl / fl CD8 was isolated from Cd4-Cre mice + T cells, treated with 10 μM SBI-477 or untreated CD8 + T cells were used to detect the expression of Txnip and Arrdc4 (n=3) by RT-qPCR.
[0115] (DF) Stimulation of CD8 with anti-CD3 / CD28 antibody + T cells were treated with 10 μM SBI-477 or not for 24 hours. + T cells, flow cytometry detection (D) and statistical analysis of CD8 + Expression of IFN-γ (E) and TNF-α (F) in T cells.
[0116] (G) Activation of CD8 in vitro with anti-CD3 / CD28 antibody + T cells were treated with SBI-477 24 hours later and effector CD8+ were removed. + T cells were co-incubated with MC38-OVA cells for 24 hours, and CD8+ were statistically analyzed. + T cell cytotoxicity (n=3-4).
[0117] (H) Separation of CD4 from peripheral blood of healthy individuals + T cells were used to induce iTreg cells, which were then treated with 10 μM SBI-477 in vitro for 24 hours. The expression of MondoA and TXNIP in iTreg cells was detected by RT-qPCR.
[0118] (I) Isolation of CD4 from peripheral blood of healthy individuals +T cells were used to induce iTreg cells, which were then treated with 10 μM SBI-477 in vitro for 24 hours. The expression of genes related to inhibitory function in iTreg cells was detected by RT-qPCR.
[0119] (JK) from MondoA fl / fl And MondoA fl / fl Treg cells were isolated from Cd4-Cre mice and CD8 cells were labeled with CTV. + T cells were mixed with Treg cells at the appropriate ratio, stimulated with anti-CD3 / CD28 magnetic beads, treated with 10 μM SBI-477 or the control group for 24 hours, and cultured for 3 days. Flow cytometry was used to detect (J) and perform statistical analysis (K) on CD8. + T cell proliferation (n=3).
[0120] Data are expressed as mean ± SEM. Two-tailed t-tests were applied in B and G. Sidak multiple comparison tests with two-way ANOVA were applied in C, E, F, H, I, and K.
[0121] Figure 11. MondoA deletion enhancement CD8 + T-cell glycolytic metabolism and mitochondrial function.
[0122] (A) In vitro stimulation of WT and MondoA-deficient CD8 cells with anti-CD3 / CD28 antibody + The mean fluorescence intensity of 2-NBDG in T cells was detected and quantified by flow cytometry after 24 hours.
[0123] (BC) Quantitative analysis of CD8 cells missing WT and MondoA + The rate of glycolysis (B) and glycolytic capacity (C) of T cells.
[0124] (DE)FromMondoA fl / fl And MondoA fl / fl CD8 was isolated from Cd4-Cre mice + T cells were stimulated with anti-CD3 / CD28 antibody for 36 hours, and CD8 levels were measured. + The concentration of glucose consumption (D) and lactate production (E) of T cells (n=8).
[0125] (FG) Quantitative analysis of CD8 cells missing WT and MondoA + Maximum respiratory capacity (F) and reserve respiratory capacity (G) of T cells.
[0126] Data are expressed as mean ± SEM. A two-tailed t-test is applied in AG.
[0127] Figure 12, SBI-477 enhanced CD8 + T cells' anti-tumor immune response in the body.
[0128] (AC) Subcutaneous tumor model was constructed by subcutaneously injecting MC38 colorectal cancer cells into wild-type mice. Images of tumor tissues in mice after treatment with solvent control or SBI-477 are shown in (A). The size (B) and weight (C) of the tumors were statistically analyzed (n=7).
[0129] (D) Flow cytometry and statistical analysis of CD8 in MC38 colorectal cancer-bearing mice treated with solvent control or SBI-477. + The mean fluorescence intensity of TXNIP in T cells (n=3).
[0130] (E) Flow cytometry and statistical analysis of CD8+ infiltrating tumor-infiltrating mice with MC38 colorectal cancer after solvent control or SBI-477 treatment. + IFN-γ and TNF-α expression in T cells (n=3).
[0131] (F) Immunofluorescence detection and statistical analysis showed that CD8+ in the tumor tissues of MC38 colorectal cancer-bearing mice treated with solvent control or SBI-477 was significantly increased. + Number of T cells (n=10).
[0132] (GI) Subcutaneous tumor model was constructed by subcutaneous injection of B16 melanoma cells into wild-type mice. Images of tumor tissues of mice after treatment with solvent control or SBI-477 were collected (G). The size (H) and weight (I) of the tumors were statistically analyzed (n=8).
[0133] (J) Quantitative analysis of CD4 infiltration in tumor-bearing mice with B16 melanoma treated with solvent control or SBI-477. + T cells and CD8 + Number of T cells (n=8).
[0134] (K) Flow cytometry and statistical analysis of CD8+ in tumor-infiltrating mice with B16 melanoma treated with solvent control or SBI-477. + Expression of IFN-γ, TNF-α and GZMB in T cells (n = 6-8).
[0135] (LN) Wild-type mice were subcutaneously injected with KPC1199 pancreatic cancer cells to construct a subcutaneous tumor model. Images (L) of tumor tissues from mice treated with solvent control or SBI-477 were collected. The size (M) and weight (N) of the tumors were statistically analyzed (n=7).
[0136] (O) Flow cytometry detection and statistical analysis of CD8+ infiltrating tumors in KPC1199 pancreatic cancer-bearing mice treated with solvent control or SBI-477. + GZMB expression in T cells (n=7).
[0137] Data are expressed as mean ± SEM. Two-tailed t-tests were applied in C, D, F, I, K, N, and O. Sidak multiple comparison tests with two-way ANOVA were applied in B, E, H, J, and M.
[0138] Figure 13, SBI-477 Enhanced CD8 + T cells' anti-tumor immune response in the body.
[0139] (AB)RT-qPCR analysis of MondoA and TXNIP expression in tumor tissue (A) and skeletal muscle (B) of tumor-bearing mice treated with solvent control or SBI-477.
[0140] (CD) Flow cytometry (C) and statistical analysis (D) CD8 counts of tumor infiltration in tumor-bearing mice after treatment with solvent control or SBI-477 + Mean fluorescence intensity of 2-NBDG in T cells (n = 6-7).
[0141] (EF) Flow cytometry detection (E) and statistical analysis (F) CD4 in draining lymph nodes of mice after solvent control or SBI-477 treatment + T cells, CD8 + T cells and CD4 + T cells and CD8 + The ratio of IFN-γ and TNF-α secreted by T cells (n=3).
[0142] (GH) Flow cytometry detection (G) and statistical analysis (H) of CD4 in the spleen of mice after solvent control or SBI-477 treatment + T cells, CD8 + T cells and CD4 + T cells and CD8 + The ratio of IFN-γ and TNF-α secreted by T cells.
[0143] Data are expressed as mean ± SEM. A two-tailed t-test was applied in D. Sidak's multiple comparison test with two-way ANOVA was applied in A, B, F, and H.
[0144] Figure 14. The combination of MondoA inhibitors and anti-PD-1 synergistically enhances the anti-tumor immune response, and MondoA inhibitors enhance the immune response against anti-PD-1 resistant colorectal tumors.
[0145] (AB) MC38 colorectal cancer-bearing mice treated with control, SBI-477, anti-PD-1 alone, or SBI-477 and anti-PD-1 in combination (A) and representative images of tumor tissue (B).
[0146] (CD) Tumor growth curves (C) and tumor weight (D) of MC38 colorectal cancer-bearing mice treated with control, SBI-477, anti-PD-1 alone, or SBI-477 and anti-PD-1 in combination (n=6).
[0147] (EF) Flow cytometry (E) and quantitative (F) analysis of tumor-invasive CD8+ in MC38 colorectal cancer-bearing mice after treatment with SBI-477, anti-PD-1 alone, or SBI-477 and anti-PD-1 in combination. + Secretion of IFN-γ in T cells (n=6).
[0148] (G) Treatment regimens for anti-PD-1 resistant MC38R tumors with SBI-477 or anti-PD-1.
[0149] (H) Representative images of tumors in MC38R tumor-bearing mice after treatment with anti-PD-1 or SBI-477.
[0150] (I) Tumor growth curves of mice treated with anti-PD-1 or SBI-477 after subcutaneous injection of MC38R cells resistant to anti-PD-1 (n=5-6).
[0151] (JL) Flow cytometry (J) and quantitative analysis (K, L) of tumor-invasive CD8+ in MC38R tumors after treatment with control, SBI-477, or anti-PD-1. + Production of IFN-γ and GZMB in T cells (n = 4-6).
[0152] Data are expressed as mean ± SEM. Paired two-tailed t-tests were applied in C and I, and unpaired two-tailed t-tests were applied in D, F, K, and L. Detailed Implementation
[0153] Through in-depth research, the inventors have for the first time revealed the relationship between the MondoA-TXNIP axis and CD8. + This is closely related to the killing effect of T cells, and it is proposed that the MondoA-TXNIP axis plays a role in regulating CD8. + A novel mechanism of T cell cytotoxicity. Based on this mechanism, this invention also provides optimized CD8... +A novel technical solution for T-cell efficacy. This invention provides a new approach for the prevention and treatment / alleviation of diseases based on the immune system.
[0154] The inventors had previously conducted some analytical studies on MondoA and TXNIP, but their focus was mainly on their regulatory roles in other cell types, rather than CD8. + T cells. The functional regulation of MondoA and TXNIP differs significantly across cell types. The inventors found that downregulating the MondoA-TXNIP axis promotes CD8... + T cells enhance glucose uptake, glycolysis, and oxidative phosphorylation metabolism, thereby boosting CD8. + The anti-tumor function of T cells. The tumors mentioned include those resistant to immune checkpoint inhibitors (blockers).
[0155] MondoA-TXNIP Axis and its Control Function
[0156] As used in this invention, the "MondoA-TXNIP axis" can also be referred to as the "MondoA-TXNIP (signaling) pathway." A "(signaling) pathway" refers to a signaling system formed by the mutual constraints or interactions between a series of genes or proteins or their metabolites (synthetic or processed products). It also includes the interaction between pathway proteins and other intracellular components or organelles, and sometimes the joint participation of upstream and downstream genes or proteins, which generally leads to certain cellular events. The "MondoA-TXNIP axis" mainly includes the following elements: MondoA gene / protein, TXNIP gene / protein; preferably, it also includes their upstream and downstream regulatory genes / proteins or chemical molecules.
[0157] As used in this invention, unless otherwise stated, the target gene / protein and the signaling pathway involved are CD8. + In T cells.
[0158] The nucleotide sequence of the MondoA gene can be shown in GenBank accession numbers NM_014938.6 (human), NM_133917.3 (mouse), and NM_177582.3 (mouse); its protein amino acid sequence can be shown in GenBank accession numbers NP_055753.3 (human), NP_598678.2 (mouse), and NP_808250.1 (mouse) (NM_133917.3 (mouse) is used as an example in this embodiment).
[0159] The nucleotide sequence of the TXNIP gene can be shown as GenBank accession numbers NM_001313972.2 (human), NM_006472.6 (human), NM_001009935.2 (mouse), and NM_023719.2 (mouse); its protein amino acid sequence can be shown as GenBank accession numbers NP_001300901.1 (human), NP_006463.3 (human), NP_001009935.1 (mouse), and NP_076208.2 (mouse) (NM_001009935.2 (mouse) is used as an example in this embodiment).
[0160] When used as targets for artificial regulation or in the creation of screening systems, the proteins or encoding genes mentioned above can be naturally occurring, such as those purified and isolated from mammals; or they can be recombinantly prepared, for example, recombinant proteins can be produced using conventional gene recombination techniques. Furthermore, any variations that do not affect the biological activity of these proteins are acceptable, such as derivatives or variants whose function remains unchanged.
[0161] The aforementioned protein (peptide) also includes its variant forms, including (but not limited to): deletions, insertions, and / or substitutions of several amino acids (typically 1-50, preferably 1-30, more preferably 1-20, most preferably 1-10, and even more preferably 1-8 or 1-5), and additions or deletions of one or more amino acids (typically up to 20, preferably up to 10, and more preferably up to 5) at the C-terminus and / or N-terminus. Any protein with high homology to the stated protein (e.g., 70% or higher homology to the peptide sequence; preferably 80% or higher; more preferably 90% or higher, such as 95%, 98%, or 99% homology) and having the same function as the protein is also included in this invention. This invention also includes a mutant form of the protein or a truncated protein, provided that the mutant protein or truncated protein substantially retains the function of the full-length protein.
[0162] The sequences of the aforementioned genes also include degenerate sequences. Polynucleotides (genes) encoding proteins can be natural genes or their degenerate sequences.
[0163] As used in this invention, the terms "downregulatory (molecule)", "downregulatory (agent)" and "inhibitor (molecule)" and "inhibitor (agent)" are used interchangeably, and also include: blockers, antagonists, etc.
[0164] The inventors have discovered that, for the MondoA-TXNIP axis, downregulating MondoA, downregulating TXNIP, and downregulating the interaction between MondoA and TXNIP can significantly enhance CD8. +T-cell killing activity. Therefore, this mode of action can be used to screen or design drugs suitable for targeted regulation.
[0165] It should be understood that, once the function of the MondoA-TXNIP axis (preferably also including its upstream and downstream proteins or genes) is known, various methods well known to those skilled in the art can be used to regulate the MondoA-TXNIP axis. For example, various methods can be used to regulate the expression of proteins within it or to suppress their expression.
[0166] This invention provides a method for regulating the MondoA-TXNIP axis, including targeted mutation, gene editing, or gene recombination of the MondoA and TXNIP genes in the MondoA-TXNIP axis, thereby achieving downregulation.
[0167] In one embodiment of this invention, a CRISPR / Cas system is used for gene editing to knock down, eliminate, or regulate target genes. Suitable sgRNA target sites lead to higher gene editing efficiency; therefore, appropriate target sites are designed and identified before gene editing. After designing specific target sites, in vitro cell activity screening is required to obtain effective target sites for subsequent experiments. This method can be used to convert MondoA and TXNIP genes into truncated or mutant versions that lose their function.
[0168] As a more specific implementation method, a method for downregulating the expression of MondoA and TXNIP genes is provided, including: transferring interfering molecules that interfere with the expression of MondoA and TXNIP genes into cells, or treating cells through appropriate pathways to introduce them into the cells, such as designing membrane-penetrating domains to enable them to cross membranes. RNA interference is a technique for silencing gene expression. The principle of RNA interference is that long double-stranded RNA is cleaved by the specific nuclease Dicer into small interfering RNAs of 21-23 nt composed of sense and antisense strands. The small interfering RNAs then form a silencing complex (RISC) that unwinds into single strands. The antisense strand guides the silencing complex to specifically bind to the target mRNA through base pairing, causing the mRNA to degrade.
[0169] Regulatory molecules
[0170] As a preferred embodiment of the present invention, downregulating molecules (downregulators) that downregulate the expression or activity of MondoA, downregulate the expression or activity of TXNIP, or downregulate the interaction between MondoA and TXNIP are provided. The downregulating molecule refers to any substance that can reduce the activity, stability, expression, activation level (e.g., alter phosphorylation level), duration of effective action, or inhibit their transcription and translation of MondoA and TXNIP. These substances can be used in the present invention as a means to enhance CD8 expression. + Substances that are useful for the killing effect of T cells. These can be small chemical molecules (compounds) or biomolecules. The biomolecules can be at the nucleic acid level (including DNA and RNA) or at the protein level.
[0171] As used in this invention, the "enhanced CD8" + "T-cell killing effect" includes: enhancing CD8 + T cell cytotoxicity, promotion of CD8 + T cells produce cytokines and suppress tumors or pathogens. The tumors include those resistant to immune checkpoint inhibitors (blockers); preferably, the immune checkpoint inhibitors include anti-PD-1, anti-PD-L1, or anti-CTLA4.
[0172] As used in this invention, "pathogen" refers to microorganisms (including bacteria, viruses, rickettsiae, fungi), parasites, or other vectors (microbial recombinants including hybrids or mutants) that infect an organism and cause disease in the organism (human or animal), and these are exogenous. In this invention, "pathogen" specifically refers to pathogens that can be detected by CD8. + T cells recognize pathogens that can infect the body. In this field, CD8 is known to be a pathogen. + T cells have a killing effect on pathogens such as viruses and tumor cells, and are an important line of defense for the body's immune system against viruses and tumors.
[0173] In this invention, the downregulating molecule can be: nucleic acid inhibitor, protein inhibitor, antibody, ligand, compound, nuclease, nucleic acid binding molecule, etc., provided that it can downregulate the expression of MondoA and TXNIP, inhibit their activity or function, or downregulate the interaction between MondoA and TXNIP (MondoA binds to the promoter of the TXNIP gene and regulates its transcription).
[0174] For example, the downregulating molecule may be: interfering RNA molecules or antisense nucleotides that specifically interfere with the expression of MondoA, TXNIP, or their upstream genes; or homologous recombination, targeted mutation, or gene editing reagents that specifically target MondoA, TXNIP, or their upstream genes, etc. A class of nucleic acid inhibitors includes: shRNAs, antisense nucleic acids, small interfering RNAs, microRNAs, or constructs that can express or form said shRNAs, antisense nucleic acids, small interfering RNAs, or microRNAs, targeting the encoding genes of MondoA, TXNIP, or their transcripts for inhibition or silencing.
[0175] As one embodiment of the present invention, homologous recombination can be used to specifically target MondoA or TXNIP, causing expression defects or deletions. Alternatively, Cre and loxp methods can be used to selectively knock out, reduce, or inactivate related genes in the genome of animals or cells.
[0176] In one embodiment of the present invention, a CRISPR / Cas (e.g., Cas9) system is used for targeted gene editing to knock out the MondoA or TXNIP gene. Common methods for knocking out the MondoA or TXNIP gene include co-transferring sgRNA or a nucleic acid capable of forming said sgRNA, Cas9 mRNA or a nucleic acid capable of forming said Cas9 mRNA, to the target region or target cell. After identifying the target site, known methods can be used to introduce sgRNA and Cas9 into the cell. The nucleic acid capable of forming said sgRNA is a nucleic acid construct or expression vector, or the nucleic acid capable of forming said Cas9 mRNA is a nucleic acid construct or expression vector. These expression vectors are introduced into the cell, thereby forming active sgRNA and Cas9 mRNA within the cell.
[0177] In one embodiment of the present invention, the downregulation molecule is an interfering molecule that specifically interferes with MondoA expression. Short hairpin RNA (shRNA) is an RNA sequence that forms a hairpin structure and can silence genes via RNA interference. The interfering molecule that specifically interferes with MondoA and TXNIP gene expression can be an shRNA molecule targeting MondoA and TXNIP genes, or a siRNA molecule targeting MondoA and TXNIP genes, etc.
[0178] In another embodiment of the present invention, the downregulating molecule is an inhibitor targeting mutations, gene editing, or gene recombination of MondoA and TXNIP. As a more specific embodiment, MondoA and TXNIP are transformed into their mutants using any of the methods described above, thereby rendering them ineffective.
[0179] In a preferred embodiment of the present invention, the downregulator is a small molecule compound targeting MondoA or TXNIP. Those skilled in the art can employ methods suitable for screening small molecule compounds to perform such screening. The screening can rely on various existing or future compound libraries in the art, or on establishing new compound libraries independently.
[0180] As a preferred embodiment of the present invention, the small molecule compound is SBI-477 (CAS No.: 781628-99-7).
[0181] In this invention, the small molecule compound (such as SBI-477) may be a compound existing in pure form, or a compound with a purity greater than 85% (preferably greater than 90%, for example greater than 95%, 98%, 99%). Knowing its chemical structure, the small molecule compound can be obtained by chemical synthesis. This invention also includes precursors of the compound, where "precursor" refers to a precursor of the compound that, when taken by an appropriate method, undergoes metabolism or chemical reaction in the patient's body to be converted into the active compound.
[0182] This invention also includes isomers, solvates, or pharmaceutically acceptable salts of SBI-477, provided they also have the same or substantially the same function as SBI-477. A "pharmaceutically acceptable salt" refers to a salt formed by the reaction of the compound with an inorganic acid, organic acid, alkali metal, or alkaline earth metal. The compound has one or more asymmetric centers. Therefore, these compounds can exist as racemic mixtures, individual enantiomers, individual diastereomers, mixtures of diastereomers, or cis or trans isomers.
[0183] Pharmaceutical Composition
[0184] The present invention also provides an enhanced CD8 + A pharmaceutical composition (or formulation) for T-cell killing / tumor inhibition or pathogen inhibition, comprising an effective amount of the downregulating molecule described in this invention.
[0185] As used herein, the term "effective amount" or "effective dose" means an amount that is functional or active in humans and / or animals and is acceptable to humans and / or animals, as used herein.
[0186] As used herein, a "pharmaceuticalally acceptable" ingredient is a substance suitable for human and / or mammalian use without excessive adverse side effects (such as toxicity, irritation, and allergic reactions), i.e., a substance with a reasonable benefit / risk ratio. The term "pharmaceuticalally acceptable carrier" refers to a carrier used for the administration of therapeutic agents, including various excipients and diluents.
[0187] As used herein, the terms “containing” or “comprising” include “comprising,” “substantially consisting of,” and “consisting of.” However, it is understood that the active ingredient (or essential component or essential part) of a pharmaceutical composition is, as specified in this invention, a downregulating molecule along the MondoA-TXNIP axis. In some embodiments, the “pharmaceutical composition” is a composition whose active ingredient is solely a downregulating molecule along the MondoA-TXNIP axis; in other embodiments, the “pharmaceutical composition” is a composition whose active ingredient is a combination of a downregulating molecule along the MondoA-TXNIP axis and an immune checkpoint inhibitor.
[0188] As used herein, the term "consistently of" means that the composition may contain, in addition to the essential ingredients or components, minor components and / or impurities that do not affect the active ingredient. For example, it may contain sweeteners to improve flavor, antioxidants to prevent oxidation, and other pharmaceutical additives, carriers, and excipients commonly used in the art.
[0189] The inventors' research also unexpectedly revealed that the co-administration of MondoA-TXNIP axis downregulation molecules with immune checkpoint inhibitors significantly enhanced the anti-tumor immune response, and the combination of the two produced an extremely significant synergistic effect.
[0190] Therefore, the present invention also provides a pharmaceutical composition comprising an effective amount of a MondoA-TXNIP axis downregulating molecule and an immune checkpoint inhibitor, and a pharmaceutically acceptable carrier.
[0191] The immune checkpoint inhibitor may be anti-PD-1, anti-PD-L1, or anti-CTLA4, etc. Preferably, the immune checkpoint inhibitor is anti-PD-1.
[0192] Typically, the downregulating molecules of the MondoA-TXNIP axis, or the molecules thereof, combined with immune checkpoint inhibitors, can be formulated in a non-toxic, inert, and cell-compatible medium, wherein the pH is typically about 5-8, and preferably about 6-8.
[0193] When using the compositions of the present invention, a safe and effective amount of the compositions of the present invention is administered to mammals. Of course, the specific dosage and frequency of administration should also take into account factors such as the patient's weight, age, and health condition, which are within the skill of those skilled in the art.
[0194] To facilitate administration, the downregulating molecules are formulated as unit dosage forms and included in the kit. "Unit dosage form" refers to a dosage form prepared for a single dose, allowing for convenient administration; this includes, but is not limited to, various liquid dosage forms (such as injections), solid dosage forms (such as tablets), capsules, and sustained-release formulations. Furthermore, the downregulating molecules can also be individually packaged in different containers and mixed as needed for application.
[0195] Although specific embodiments of the present invention provide dosing regimens for animals such as mice, it should be understood that converting animal dosages to human dosages is readily achievable by those skilled in the art, for example, using the Meeh-Rubner formula: Meeh-Rubner formula: A = k × (W 2 / 3 ) / 10,000. Where A is the body surface area, expressed in meters. 2 Calculations; W is body weight, expressed in grams; K is a constant that varies depending on the animal species, for example, but not limited to: mice and rats 9.1, guinea pigs 9.8, rabbits 10.1, cats 9.9, dogs 11.2, monkeys 11.8, and humans 10.6. It should be understood that dosage conversions may vary depending on the drug and clinical circumstances, and are based on the assessment of an experienced pharmacist.
[0196] The pharmaceutical compositions of the present invention can be directly used to enhance CD8. + T-cell killing effect / inhibition of tumors or pathogens. In addition, it can be used in combination with other therapeutic agents or adjuvants.
[0197] This invention provides a method for enhancing CD8 + A kit for T-cell killing / tumor inhibition or pathogen inhibition, the kit comprising: an effective amount of the downregulating molecule described in this invention. More preferably, the kit further comprises: instructions for use to guide clinicians in the correct and appropriate use of the medication.
[0198] The present invention also provides a method for enhancing CD8 + A cassette for T-cell killing / tumor inhibition or pathogen inhibition, comprising: container 1, comprising an effective amount (e.g., 1-1000 μM) of a downregulating molecule of the MondoA-TXNIP axis, and a pharmaceutically acceptable carrier; and container 2, comprising an effective amount (e.g., 0.01-1000 mg) of an immune checkpoint inhibitor, and a pharmaceutically acceptable carrier.
[0199] The described medicine box is designed for ease of use by those skilled in the art, particularly clinicians. As a preferred embodiment of the invention, the medicine box also includes an instruction manual to guide those skilled in the art in administering the medication using appropriate methods.
[0200] Drug screening based on the MondoA-TXNIP axis
[0201] Based on the inventor's new discovery, the study of the MondoA-TXNIP axis has multiple applications, including: screening substances that modulate the MondoA-TXNIP axis in order to enhance CD8. + The cytotoxic effect of T cells. The regulation includes: downregulating MondoA, downregulating TXNIP, and downregulating the interaction between MondoA and TXNIP.
[0202] As used in this article, "inhibition" and "downregulation" refer to statistically significant "inhibition" and "downregulation," that is, significant "inhibition" and "downregulation." For example, compared with the control group, protein activity, protein expression, protein binding, or methylation level, significant "inhibition" or "downregulation" of 10%, 20%, 30%, 40%, or 50% or more; better, 60%, 70%, or 80% or more.
[0203] The system containing the MondoA-TXNIP axis is selected from: cell systems (or cell culture systems), subcellular systems (or subcellular culture systems), solution systems, animal systems, or tissue systems (or tissue culture systems). Preferably, the system containing the MondoA-TXNIP axis is CD8. + T cells (or cell cultures).
[0204] As a preferred embodiment of the present invention, the method further includes: conducting further cell experiments and / or animal experiments on the obtained potential substances to further select and determine from the candidate substances the effects on enhancing CD8. + T cells have the ability to kill pathogens and promote the elimination of tumors or pathogens.
[0205] When screening, various techniques well known in the art can be used to determine the variations and interactions of proteins or their encoding genes.
[0206] A variety of conventional techniques can be used to identify gene transcription or expression in a system. These techniques include, but are not limited to, oligonucleotide hybridization (e.g., probes), polymerase chain reaction (PCR), and polyacrylamide gel electrophoresis. Detecting protein-protein interactions and their strength can be achieved using various techniques well-known to those skilled in the art, such as immunoprecipitation, GST precipitation, phage display, or yeast two-hybrid systems. Nuclear localization of proteins is also a well-known technique in the field.
[0207] The substances initially screened using the above method can form a screening library, which will allow researchers to ultimately select substances that can enhance CD8. + T cells are truly useful substances for killing tumors or inhibiting pathogens.
[0208] The present invention also provides CD8 enhancement methods that can be used to obtain CD8 using the aforementioned screening method. + T cells have the potential to kill tumors or inhibit pathogens.
[0209] The present invention also provides a method for preparing enhanced CD8 + Methods for using drugs to kill T cells, inhibit tumors, or suppress pathogens, the methods comprising: synthesizing and / or purifying the aforementioned screened useful substances as agents for enhancing CD8. + T-cell killing effects, drugs that inhibit tumors or pathogens.
[0210] Methods for screening substances that act on proteins or genes or specific regions thereof as targets are well known to those skilled in the art, and these methods can all be used in this invention. The candidate substances can be selected from: peptides, polymeric peptides, peptide-like substances, non-peptide compounds, carbohydrates, lipids, antibodies or antibody fragments, ligands, small organic molecules, small inorganic molecules, and nucleic acid sequences, etc. Depending on the type of substance to be screened, those skilled in the art understand how to select an appropriate screening method.
[0211] Application in prognostic assessment of cell function
[0212] This invention has discovered that CD8+ in pathological environments (such as those where lactic acid is produced and induced by lactic acid) + T cell dysfunction occurs, with upregulation of MondoA function and enhanced binding to the promoter region of TXNIP or its homolog (ARRDC4). MondoA function is also affected by CD8. + The MondoA-TXNIP axis plays a crucial role in T cell dysfunction. Therefore, the aforementioned performance of the MondoA-TXNIP axis can serve as a guide for CD8... +Molecular markers for prognosis (including medication guidance) of T cell's ability to suppress tumors or pathogens include: (i) disease subtyping and differential diagnosis; (ii) assessing treatment drugs, drug efficacy, prognosis, and selecting appropriate treatment methods for relevant populations. For example, individuals with abnormal (enhanced) MondoA gene expression or abnormal (enhanced) TXNIP gene expression can be isolated, allowing for more targeted treatment.
[0213] Typically, in CD8 + In T cells, a threshold for MondoA or TXNIP expression can be defined. When the expression level of MondoA or TXNIP exceeds the defined threshold, treatment should consider using a regimen that inhibits MondoA or TXNIP. This threshold is easily determined by those skilled in the art, for example, by modifying CD8+ expression from the patient's T cells. + After comparing and analyzing the expression of MondoA in T cells or in normal healthy individuals, a threshold for abnormal MondoA expression was obtained.
[0214] Therefore, this invention provides the use of the MondoA-TXNIP axis for the fabrication of CD8... + Reagents or kits for prognostic assessment of T-cell killing / tumor suppression or pathogen inhibition capabilities. Various techniques known in the art can be used to detect the presence and expression of corresponding genes or proteins, all of which are included in this invention. For example, existing techniques such as Southern blotting, Western blotting, DNA sequencing, and PCR can be used, and these methods can be used in combination. This invention also provides reagents for detecting the presence and expression of genes or proteins in analytes. Preferably, when performing gene-level detection, primers for specific amplification or probes for specific recognition can be used to determine the presence of the target gene; when performing protein-level detection, antibodies or ligands that specifically bind to the protein can be used to determine the expression of the target protein.
[0215] The kit may also include various reagents required for DNA extraction, PCR, hybridization, and color development, including but not limited to: extraction buffer, amplification buffer, hybridization buffer, enzymes, control solution, color development solution, and washing buffer. Furthermore, the kit may also include an instruction manual and / or nucleic acid sequence analysis software.
[0216] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments that do not specify specific conditions are generally performed according to conventional conditions such as those described in J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Science Press, or according to the manufacturer's recommendations.
[0217] Materials Methods
[0218] mice
[0219] All mouse lines are of the C57BL / 6J genetic background. Cd4-Cre, OT-I TCR transgenic mice, CD45.1 + The mice were purchased from Jackson's laboratory.
[0220] MondoA-deficient mice (MondoA) fl / fl Cd4-Cre): A loxP sequence was inserted flanking exons 2 and 3 of the MondoA gene in the C57BL / 6J mouse genome to obtain MondoA knockout genes. fl / fl Mice. MondoA fl / fl Mice were mated with Cd4-Cre mice to produce mice with MondoA knocked out in T cells.
[0221] MondoA fl / fl Mice were crossed with Cd4-Cre transgenic mice to produce age-matched MondoA mice. fl / fl And MondoA fl / fl Cd4-Cre mice. OT-I mice were compared with MondoA. fl / fl Cd4-Cre mouse hybridization, thereby achieving CD8 + The MondoA gene was specifically knocked out in T cells. All mice were housed in a pathogen-free environment at an animal center. Unless otherwise stated, all experiments used sex-matched mice aged 6–8 weeks.
[0222] RNA extraction and quantitative PCR
[0223] Following the instructions, total RNA was extracted from cells using Trizol (Invitrogen Life Technologies, Cat#15596018) and a kit (Qiagen, Cat#74104). RNA concentration was quantified using a NanoDrop instrument (Thermo). RNA was reverse transcribed into complementary DNA using the PrimeScript RT Master Mix kit (Takara, Cat#RR037A). The target gene was quantified using the SYBR green Premix Ex Taq kit (Takara, Cat#RR420A) and real-time quantitative PCR. Quantitative PCR was performed using StepOne Plus real-time PCR (ABI). Two [samples were used]. -ΔΔCT The relative expression level of mRNA was calculated using the method. The primer sequences used for quantitative PCR are listed in Table 1.
[0224] Table 1
[0225] Western blot analysis of proteins
[0226] For protein expression analysis, suspended immune cells were collected into centrifuge tubes, centrifuged at 300g for 5 min at 4°C, the supernatant was discarded, the cell pellet was collected and washed with ice-cold PBS, and an appropriate amount of cell lysis buffer (20mM Tris, pH 7.5, 150mM NaCl, 1% Triton X-100) was added, the mixture was dispersed and mixed, and the mixture was placed in a 4°C resuspending apparatus and rotated for 30 min to ensure complete lysis. Total protein was extracted on ice. Protein concentration was determined using the BCA protein assay kit (20201-A) for protein quantification. Protein samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Cat#ipvh00010). The membrane was blocked with 5% bovine serum albumin, incubated with primary antibody overnight at 4°C, and then incubated with enzyme-linked secondary antibody at room temperature for 1 h. Chemiluminescence detection was performed using an ECL assay kit (Millipore, Cat#WBULS0500). The primary antibodies used were MondoA (Bethyl, Cat#A303-195A), TXNIP (Abcam, Cat#ab188865), and β-actin (Proteintech, Cat#66009-1).
[0227] In vitro CD8 + T cell activation
[0228] From MondoA fl / fl Or MondoA fl / flSpleens and lymph nodes were isolated from Cd4-Cre mice. The extracted mouse tissues were ground using a ground glass slide and filtered through a 300-mesh sieve into 15 mL centrifuge tubes. Centrifugation at 300g for 5 min was performed, and the supernatant was removed to obtain a single-cell pellet. Red blood cells were then lysed. T cells were then enriched using MACS magnetic beads via negative selection according to the manufacturer's instructions (Miltenyi Biotec). The enriched T cells were counted for subsequent sorting. After sorting, cells were resuspended in RPMI medium (1% sodium pyruvate, 1% glutamine, 1% Pen / Strep, 0.1% β-mercaptoethanol) with 100 U / mL IL-2 (RD Biotec, Cat#402-ML) added. Resting CD8+ cells were activated using 2 μg / mL anti-mouse CD3 (biolgend, Cat#100314) coated into 24-well plates and 3 μg / mL soluble anti-mouse CD28 (biolgend, Cat#102112). + T cells. For OTI CD8 + T cell culture involved adding 2 μg / ml of SINFELK peptide (Sigma-Aldrich, Cat#S7951) to the culture medium. Cells were then further treated with control, lactate (Sigma-Aldrich, Cat#L6402), or sodium lactate.
[0229] Flow cytometry
[0230] Single-cell suspensions were isolated from mouse thymus, spleen, and lymph node tissues. For surface marker analysis, FACS buffer (formulated as 500 μL of 10% FBS and 200 μL of 0.5M EDTA per 50 mL of 1xPBS) was used. The required surface antibody and live / inactivated dye were added according to the antibody labeling instructions (eBioscience, Cat#65-0865-14), and the mixture was stained at 4°C in the dark for 30 min.
[0231] To detect intracellular cytokines, cells were stimulated for 4–6 h in mouse RPMI 1640 medium containing 0.25 μg / mL PMA (Sigma-Aldrich, Cat#P1585), 0.25 μg / mL Ionomycin (Sigma-Aldrich, Cat#I3909), and 1:1000 Golgistop (BD Bioscience, Cat#554724). After stimulation, cell surface staining was performed first, followed by fixation and perforation using a transcription factor staining kit (eBioscience, Cat#00-5523-00), and then staining with cytokine antibodies.
[0232] To analyze glucose uptake, cells were cultured for 30 min in glucose-free RPMI 1640 medium containing 2% FBS, then stained with 100 μM 2-NBDG (Invitrogen Life Technologies, Cat#N13195) in PBS at 37°C for 30 min; mitochondrial membrane potential was then analyzed by incubating with 5 μM MitoTracker Red CMXRos (Invitrogen Life Technologies, Cat#M7512) in a 37°C, 5% CO2 incubator. Cells were washed three times with FACS buffer and then stained for further analysis.
[0233] To analyze TXNIP in CD8 + For T cell expression, cells were first subjected to cell viability testing and staining with cell surface antibodies. Then, a nuclear membrane permeation working solution was prepared at a 3:1 ratio of Fixation / Permeabilization Diluent:Concentrate. Cells were resuspended in the permeabilization working solution and fixed at 4°C in the dark for 30 min. Cells were then stained with TXNIP antibody (Proteintech, Cat#18243-1-AP) at 4°C in the dark for 1 h, followed by staining with fluorescent secondary antibody (Life Technologies, Cat#A-11008; Cell Signaling Technology, Cat#2729) at 4°C in the dark for 30 min. All samples were collected using an LSR Tortessa X-20 flow cytometer (BD Bioscience), and data analysis was performed using FlowJo software.
[0234] Metabolic analysis
[0235] Activation of CD8 using CD3 / CD28 antibody + T cells were collected after 36 hours, and the cell supernatant was collected. Glucose consumption and lactate production were analyzed using a glucose assay kit (Nanjing Jiancheng Biotechnology Institute, Cat#F006-1-1) and a lactate assay kit (Sigma-Aldrich, Cat#MAK064).
[0236] Extracellular acidification rate (ECAR) and oxygen consumption (OCR) were analyzed using a Seahorse XF96 extracellular flux analyzer (Agilent), following the manufacturer's instructions. In short, from MondoA... fl / fl And MondoA fl / fl CD8 was isolated from Cd4-Cre mice +T cells were stimulated for 24 hours using CD3 / CD28 antibody magnetic beads. Activated CD8 + T cells were seeded into XF96-well plates pre-coated with Cell-Tak (BD Biosciences, Cat#354240) at a density of 3 × 10⁶ cells per well. 5 Each cell was placed in a 37°C CO2-free incubator and cultured for 30 minutes, ready for instrumental analysis.
[0237] Glycolysis was measured using a glycolysis stress test kit (Agilent, Cat#103020). Three baseline records were taken, followed by sequential injections of 10 mM glucose, 1 μM oligomycin, and 100 mM 2-deoxyglucose. OCR was analyzed using a mitochondrial stress test kit (Agilent, Cat#102601). Three baseline records were taken, followed by sequential injections of 2 μM oligomycin, 2 μM FCCP, and 0.5 μM rotenone / antimycin. Data were analyzed using Wave software.
[0238] Immunofluorescence staining
[0239] From MondoA fl / fl Or MondoA fl / fl CD8 sorting in Cd4-Cre mice + T cells (3x10 per well) 5 Cells were centrifuged to ensure full contact with pre-coated poly-L-lysine (Sigma-Aldrich, Cat#P7886) in 24-well plates. Cells were fixed with 4% paraformaldehyde at room temperature for 10 min. Cells were blocked with 5% goat serum at room temperature for 1 h, then incubated overnight at 4°C on a shaker with antibodies against GLUT1 (Abcam, Cat#ab115730), MondoA (Proteintech, Cat#13614-1-AP), TXNIP (Abcam, Cat#ab188865), or CD8 (Servicebio, Cat#GB13429). Cells were then washed three times with PBS and incubated for 1 h at room temperature with Alexa Fluor 555 (Life Technologies, Cat#A-32732) or Alexa Fluor 488-labeled goat anti-rabbit IgG (Life Technologies, Cat#A-11008). Cell nuclei were stained using DAPI (YEASEN, Cat#40728ES03) at room temperature for 10 min. After washing three times with PBS, the stained cell discs were transferred to a glass slide (YEASEN, Cat#36307ES08) and observed under a confocal microscope (Leica, TCS SP8 STED) for staining analysis.
[0240] In vitro Treg cell immunosuppression experiment
[0241] Wild-type CD8 after flow cytometry sorting + T cells and Treg cells were collected separately into 15 mL centrifuge tubes, centrifuged at 300 g for 5 min, and the supernatant was discarded. The cells were then treated with 1 μL of 5 mM Cell Trace. TM Violet dye (Invitrogen Life Technologies, Cat#34557) was added to 1 mL of CD8. + T cell suspension was incubated at 37°C in the dark for 10 min and labeled with CD8. + T cells. Labeled CD8 + T cells cultured alone or with Treg cells (CD4+) isolated from wild-type mice + CD25 hi Cells were co-cultured at different ratios and stimulated with anti-CD3 / CD28 antibody magnetic beads (Invitrogen Life Technologies, Cat#11131D) for 3 days. For SBI-477 (Selleck, Cat#S3187) treatment, cells were cultured for 48 hours with or without 10 μM SBI-477. CD8 counts on day 3 after SBI-477 treatment were analyzed by flow cytometry. + The proliferation of T cells indirectly reflects the strength of the inhibitory function of Treg cells in vitro.
[0242] Tumor models and treatment
[0243] Colorectal cancer, B16 melanoma, and KPC1199 pancreatic cancer cells (3×10⁻⁶) were induced in MC38 mice. 5 A subcutaneous colorectal cancer tumor model was established by subcutaneously injecting MC38-OVA colorectal cancer cells (3 × 10⁻⁶ cells) into the skin of 6-8 week old mice. 5 Seven days after tumor inoculation, tumor-bearing mice with similar tumor sizes were randomly divided into two groups. The two groups of mice were intravenously injected with MondoA... fl / fl OTI or MondoA fl / fl CD86-sorted from Cd4-Cre OTI mice + T cells. For SBI-477 treatment, 6-8 week old wild-type mice were inoculated with 3 × 10⁻⁶ cells. 5Mice were inoculated with MC38 colorectal cancer cells. Starting from day 7 post-inoculation, mice with similarly sized colorectal tumors were randomly divided into two groups. Simultaneously, mice received subcutaneous injections of SBI-477 (50 mg / kg) or a solvent control every two days. For anti-PD-1 treatment, mice were intraperitoneally injected with anti-PD-1 (BioxCell, Cat#BE0146) every three days at a dose of 100 mg per mouse, for a total of five injections. Unless otherwise specified, tumor growth was monitored every two days starting from day 7 post-inoculation. Tumor size was expressed as length (mm) × width (mm). Mice with tumors reaching 20 mm in diameter in any direction were euthanized.
[0244] Specimens from colorectal cancer patients
[0245] Colorectal cancer tissue and matched normal tissue were obtained from Xinhua Hospital affiliated with Shanghai Jiao Tong University. This study was approved by the Ethics Committee of Xinhua Hospital (XHEC-D-2020-075), complied with all relevant ethical regulations, and informed consent was obtained from all patients. Tumor and normal tissues were freshly isolated and digested to prepare tissue-infiltrating lymphocytes. Further analysis was performed using flow cytometry.
[0246] In vitro tumor killing experiment
[0247] CD8 isolated from OTI mice + T cells, at 1×10 6 CD8 was seeded at a density of cells / well in a 24-well plate. + T cells were activated with CD3 / CD28 antibody for 24 hours, and then the activated CD8 cells were... + T cells were treated with either control or SBI-477 for 24 hours, followed by counting of MC38-OVA tumor cells and CD8+. + T cells were seeded at a ratio of 1:20 into corresponding 96-well plates and co-cultured for 4 hours. The cell supernatant was then collected for CD8 assay. + T-cell cytotoxicity assay (Promega, Cat#G1780).
[0248] Electron microscopy observation of mitochondrial morphology
[0249] Activation of CD8 with CD3 / CD28 antibody + T cells, CD8 cells treated with control or lactate + T cells were collected over 24 hours, with 1 × 10⁻⁶ cells. 7 One activated CD8 +T cells were centrifuged, the supernatant was discarded, and 5 mL of fixative (2.5% glutaraldehyde dissolved in 100 mM sodium dimethylarsinate) was added. The mixture was then dispersed and incubated at 4°C for 24 h. After fixation, the cells were washed, dehydrated, and embedded. Each sample was cut into multiple 50 nm sections, and mitochondrial morphology was observed and photographed using a JOEL 1200EX transmission electron microscope. Electron microscopy analysis was performed using a JOEL 1200EX transmission electron microscope. The number of mitochondria, the number of mitochondrial cristae, and the width of mitochondrial cristae were calculated using the ImageJ image analysis system.
[0250] Chromatin immunoprecipitation (ChIP)
[0251] Chromatin immunoprecipitation was performed according to the method published in Nature Protocols in 2008. In short, cross-linked cells were collected, lysed, and sonicated to break down chromatin into fragments of approximately 500-800 bp. The sonicated samples were then divided into input controls and ChIP samples. Dynabeads Protein G (Invitrogen Life Technologies, Cat#10003D) was incubated with 1 mg of negative control IgG (Cell Signaling Technology, Cat#2729) or MondoA antibody at 4°C for 2 hours. Then, the ChIP samples were added and incubated at 4°C for 2 hours. Input and ChIP samples were incubated with proteinase K (Beyotime Biotechnology, Cat#ST535) at 55°C for 30 min to ensure protein digestion. DNA was extracted and purified from the input and ChIP samples using 10% Chelex-100 (Bio-Rad, Cat#142-1253) and used as PCR templates. Primers specifically targeted the TXNIP and ARRDC4 promoters. Primers are listed in Table 1.
[0252] RNA-seq sequencing and analysis
[0253] Sample preparation: CD8 groups were isolated from PBMCs of healthy individuals. + T cells and CD4 + T cells, cell purity >98%. For CD8... + T cells were activated for 24 hours in X-VIVO T cell culture medium using CD3 / CD28 antibody magnetic beads, followed by treatment with either a control or 10mM lactate for 24 hours. For CD4... + T cells will release CD4 +T cells were polarized into induced Treg cells in vitro using CD3 / CD28 antibody magnetic beads, 100 U / mL IL-2, and 5 ng / mL transforming growth factor (TGF-β) (RD Biotec, Cat#6666-mb), and treated with either control or 10 mM lactate for 24 h; from 6-8 week old MondoA cells fl / fl And MondoA fl / fl CD8 sorting in Cd4-Cre mice + T cells were activated in vitro with CD3 / CD28 antibody for 24 hours. CD8 cells were extracted using the RNeasy Mini Kit (Qiagen, Cat#74104). + Total RNA from T cells and induced Treg cells was collected and analyzed using RNA-seq.
[0254] Reads were aligned to genomes (mouse genome GRCm39 and human genome GRCh38) using Hisat2, and featurests were counted. Differential expression analysis between groups was performed using Deseq2. Genes with a p-value <0.05, upregulated gene fold change ≥1.5, or downregulated gene fold change ≤0.75 were considered statistically significant.
[0255] GSEA pathway analysis was performed on differentially expressed genes using the Broad Research (www.gsea-msigdb.org / gsea / msigdb) h.all.v2023.2.Hs.symbols.gmt and mh.all.v2023.Mm.symbols.gmt databases.
[0256] Statistical analysis
[0257] Statistical analysis was performed using Prism 9 (GraphPad software), and results are expressed as mean ± standard error of the mean (sem). Comparisons between two groups were performed using unpaired or paired two-tailed Student's t-test. Comparisons among multiple groups were performed using Tukey's multiple comparison test (one-way ANOVA) and Sidak's or Tukey's multiple comparison test (two-way ANOVA). P-values not statistically significant are indicated as "ns" in the figures. Statistical analysis of the data can be found in the legend.
[0258] Example 1: Lactic acid upregulates Treg and CD8 + T cell TXNIP and ARRDC4 expression
[0259] Lactic acid secreted by tumor cells maintains the immunosuppressive function of Treg cells and inhibits CD8. +The effector function of T cells contributes to tumor immune escape. Therefore, it is necessary to investigate the regulation of Treg and CD8 by lactate. + The molecular mechanisms of T cell function are crucial. The inventors analyzed Treg cells and CD8 cells in the control and lactate groups. + RNA sequencing data of T cells were analyzed, and the gene expression profiles of the two sequencing data sets were compared to identify 61 common differentially expressed genes (Figure 1A). Importantly, the inventors found that TXNIP was one of the most significantly upregulated differentially expressed genes (Figure 1B-E), and the expression of ARRDC4, a homolog of TXNIP, was also significantly upregulated (Figure 2A, B).
[0260] Quantitative real-time PCR results confirmed that lactate significantly upregulated Treg and CD8. + Expression of TXNIP and ARRDC4 in T cells (Figure 1F-G).
[0261] Meanwhile, lactate significantly upregulated Treg and CD8. + Protein levels of TXNIP in T cells (Figure 1H-I).
[0262] Moreover, detection with Treg and CD8 + The expression of T cell function-related genes was found to be reduced by lactate, which is associated with CD8. + The expression of T cell function-related genes was reduced, but the expression of Treg cell characteristic genes was increased (Figure 1J, K).
[0263] The inventors treated CD8 with lactic acid or sodium lactate. + T cells were used to investigate the regulation of TXNIP by these metabolites. The results showed that lactate promoted the mRNA and protein expression of TXNIP, but sodium lactate did not affect TXNIP expression (Figure 2C, D). Notably, Treg cell inhibition experiments showed that lactate enhanced the inhibition of CD8 by Treg cells. + Inhibition of T cell proliferation (Figure 1L).
[0264] These results indicate that lactate upregulates Treg and CD8. + The expression of TXNIP and ARRDC4 in T cells is also observed. More importantly, lactate enhances the inhibitory effect of Treg cells and weakens CD8+. + T-cell cytotoxicity.
[0265] Example 2: MondoA-TXNIP axis on CD8 + T cell dysfunction plays an important role
[0266] TXNIP and ARRDC4 play key roles in regulating glucose uptake. To investigate whether lactate regulates CD8... +Glucose uptake by T cells was detected using a 2-(N-(7-nitrobenzene-2-oxo-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) probe. Results showed that lactate decreased CD8 uptake. + Glucose uptake by T cells (Fig. 3A, B).
[0267] The inventors will next verify whether lactic acid regulates CD8. + MondoA transcriptional activity in T cells. Immunofluorescence showed that lactate promotes CD8 transcription. + Nuclear translocation of MondoA in T cells (Fig. 3C, D).
[0268] Chromatin immunoprecipitation assays further showed that, compared with the control group, CD8 under high lactate conditions... + In T cells, MondoA binds more strongly to the promoter regions of the TXNIP and ARRDC4 genes (Figure 3E).
[0269] However, the therapeutic role of SBI-477 in anti-tumor immunotherapy remains unexplored. Further investigation is needed to determine whether and how SBI-477 regulates CD8. + The inventors treated CD8 cells with SBI-477 to enhance the transcriptional activity of MondoA in T cells. + T cells showed that the mRNA and protein levels of TXNIP were significantly downregulated (Figure 3F, G).
[0270] Chromatin immunoprecipitation assays revealed that SBI-477 attenuated CD8+. + MondoA binds to its target genes TXNIP and ARRDC4 promoter regions in T cells (Fig. 3H, I). Therefore, SBI-477 inhibits CD8... + The transcriptional activity of MondoA in T cells.
[0271] To investigate how MondoA affects CD8 + T cell function, CD8 isolated from wild-type mice + T cells were treated with lactate, SBI-477, or a combination of both. Flow cytometry results showed that lactate damaged CD8 cells. + T cell function, while inhibition of MondoA alleviates the effects of lactate on CD8. + Impairment of T cell function (Figure 3 J-M).
[0272] In summary, CD8 + The MondoA-TXNIP axis exists within T cells, and this axis is located in CD8. + T cells play an important role in T cell dysfunction.
[0273] Example 3: MondoA knockout enhances in vivo tumor infiltration CD8 + T-cell anti-tumor immunity
[0274] To further investigate the role of the MondoA-TXNIP axis in T cells in vivo, we used MondoA... fl / fl Mice were crossed with Cd4-Cre mice to produce conditional knockout mice (MondoA knockout mice) with a specific deletion of MondoA in T cells. fl / fl Cd4-Cre mice). Quantitative real-time PCR and Western blot analysis confirmed the presence of [a specific substance] in CD8 [a specific cell / organization]. + MondoA-specific deletion in T cells (Fig. 5A, B).
[0275] The inventors discovered that a lack of MondoA does not affect MondoA. fl / fl Thymocyte development and T cell ratios in the spleen (SP), peripheral lymph nodes (pLN), and mesenteric lymph nodes (mLN) of Cd4-Cre mice (Figure 6A-E). MondoA fl / fl Cd4-Cre and MondoA fl / fl CD44 in the spleen, peripheral lymph nodes, and mesenteric lymph nodes of mice hi CD62L lo The proportion of T cells did not change significantly (Fig. 6F, G). MondoA-deficient mice showed a slight increase in Ki-67 expression in the spleen and mesenteric lymph nodes, but no change in peripheral lymph nodes (Fig. 6H, I). MondoA deficiency did not alter CD8 expression in the spleen and lymph nodes. + T cell effector cytokine production (Figure 6J). These data indicate that T cell-specific loss of MondoA does not alter thymus development or T cell homeostasis in mice.
[0276] To further evaluate whether the MondoA-TXNIP axis modulates CD8 in vivo. + The killing function of T cells was studied using a subcutaneous xenograft model of MC38 colorectal cancer cells. Notably, the inventors observed that conditional knockout of MondoA cells... fl / fl Tumor reduction in Cd4-Cre mice (Fig. 4A, B). MondoA fl / fl Tumor-infiltrating CD8 in Cd4-Cre mice + The number of T cells increases (Figure 4C).
[0277] MondoA deficiency promotes tumor-invasive CD8. + T cell IFN-γ production (Fig. 4D, E). In contrast, MondoA... fl / fl Cd4-Cre and MondoAfl / fl Tumor-invasive CD4 in mice + There was no significant change in IFN-γ production in T cells (Fig. 4D, E).
[0278] The inventors discovered that MondoA fl / fl CD4 in the draining lymph nodes of Cd4-Cre mice + Decreased percentage of T cells, CD8 + The percentage of T cells is increased (Fig. 9A, B). Meanwhile, CD4+ levels in the draining lymph nodes of MondoA-deficient and wild-type mice are higher. + T cells and CD8 + There was no significant difference in cytokine secretion by T cells (Figure 9C-E).
[0279] These data indicate that MondoA plays an important role in the T-cell anti-tumor immune response in vivo.
[0280] CD8 + T-cell responses are crucial for combating tumor immunity, but their activity is suppressed in the tumor microenvironment. Therefore, developing effective therapies to enhance CD8 activity is essential. + The anti-tumor activity of T cells is of great significance. To further investigate the effect of MondoA on antigen-specific CD8... + Regulation of T cell function, through MondoA fl / fl Cd4-Cre mice were crossed with ovalbumin-specific TCR transgenic (OT-I) mice to establish CD8 + Conditional knockout mice that specifically lack MondoA in T cells (named MondoA) fl / fl Cd4-Cre OT-I mice).
[0281] Next, from MondoA fl / fl Cd4-Cre OT-I and MondoA fl / fl CD8 isolated from OT-I mice + T cells were adoptively transferred to tumor-bearing mice. The results showed that, compared to control mice, the transfer of MondoA-specifically knocked-out CD8+ cells was more effective. + T cells in mice resulted in smaller tumors and stronger anti-tumor activity (Fig. 4F, G).
[0282] The inventors discovered that MondoA deficiency increases tumor-invasive CD8. + T cells secrete IFN-γ, enhancing CD8 + Effector functions of T cells (Fig. 4H, I).
[0283] Furthermore, MondoA deficiency promotes the drainage of CD8 in lymph nodes. +T cell IFN-γ production (Fig. 9F, G).
[0284] To investigate the role of MondoA in a lactate-mediated immunosuppressive environment, the inventors constructed CD8... + A co-culture system for T cells and MC38 colorectal cancer cells. The inventors were in CD8... + T cells reduced lactate concentrations secreted by colorectal cancer cells by knocking out MondoA or inhibiting MondoA with the inhibitor SBI-477, and by targeting LDHA with shRNA or inhibiting LDHA with the LDHA inhibitor oxamate in MC38 colorectal cancer cells (Figure 4J, K). The results indicate that lactate damages CD8+. + T cell tumor-killing ability (Figure 4L). SBI-477 treatment significantly reduced the effect of lactate on CD8 cells. + Inhibition of T cell killing function (Figure 4L). Furthermore, the inventors incorporated LDHA... high and LDHA low MC38 colorectal cancer cells were subcutaneously injected into WT and MondoA knockout mice. Results showed that, compared with LDHA... low Compared to MC38 colorectal cancer cells, LDHA injection... high The mouse tumors of MC38 colorectal cancer cells were larger and more infiltrated with CD8. + Reduced cytokine secretion by T cells, MondoA deficiency eliminates the pro-tumor effect of lactate and its effect on CD8. + The inhibitory effect of T cytokine secretion (Figure 4M, N). These data indicate that MondoA deficiency significantly reduces the effect of lactate on CD8. + The inhibitory effect of T cell anti-tumor activity. Importantly, targeting the MondoA-TXNIP axis is a potential therapeutic strategy to counteract the lactate-induced immunosuppressive microenvironment.
[0285] Example 4: Lactic acid and TCR / CD28 signaling coordination CD8 + TXNIP expression in T cells
[0286] CD8 + T cells exert their effector functions after activation by TCR and CD28. However, in the tumor microenvironment, tumor cells inhibit T cell infiltration and activation, leading to T cell dysfunction. The inventors analyzed public single-cell data on resting (Tn) and effector memory (Tem) CD28. + Differential gene expression in T cell subsets and its correlation with lactate-treated CD8 + By intersecting differentially expressed genes in T cell RNA sequencing data, eight common differentially expressed genes were identified, among which TXNIP showed the most significant change (Figure 7A).
[0287] To investigate CD8 + The regulation of antitumor activity of TXNIP in T cells was investigated by flow cytometry analysis of CD8+ in normal human colon tissue and colon tumor-infiltrated cells. + The expression of TXNIP in T cells was investigated, revealing that TXNIP is involved in CD8+ invasive cells of human colon tumors. + Increased expression in T cells (Figure 7B). In addition, the inventors further analyzed single-cell RNA sequencing data from colorectal cancer patients (Zhang et al., 2020). Notably, compared with resting CD8... + Compared to T cells, the effector CD8+ cells in tumor infiltration + TXNIP expression was significantly downregulated in T cells (Figure 7C). Quantitative real-time PCR and immunoblotting analysis revealed that TXNIP expression was significantly downregulated in activated CD8+ cells. + TXNIP expression was significantly downregulated in T cells (Fig. 7D, E). These results indicate that TXNIP downregulation is a key factor in tumor infiltration by CD8+. + T cells are essential for T cells to function.
[0288] Effect CD8 + T cells primarily rely on glycolysis to support their proliferation and function, similar to resting CD8+ cells. + Compared to T cells, effector CD8 cells activated by anti-CD3 and anti-CD28 antibodies... + The extracellular acidification rate (ECAR) of T cells was significantly increased (Figure 7F-H). To further elucidate whether TCR / CD28 signaling regulates CD8... + The transcriptional activity of MondoA in T cells was investigated using immunofluorescence assays, which revealed that TCR / CD28 signaling inhibited MondoA nuclear translocation (Fig. 7I,J). Furthermore, chromatin immunoprecipitation assays showed that TCR / CD28 signaling inhibited the binding of MondoA to the TXNIP promoter region (Fig. 7K). These results indicate that, contrary to the effect of lactate increasing TXNIP expression, TCR / CD28 signaling inhibits the transcriptional activity of MondoA, leading to CD8+ translocation. + TXNIP expression is downregulated in T cells.
[0289] Next, we investigated whether lactate affects the regulation of TXNIP expression by TCR / CD28 signaling. The results showed that lactate inhibited the suppression of TXNIP expression by TCR / CD28 signaling, while the downregulation of TXNIP affected CD8 expression. + T cell activation plays a crucial role (Figure 7L). As expected, it is associated with resting CD8+. + Compared to T cells, TCR / CD28 signaling promotes CD8 +Expression of activation-signature gene CD44 and proliferation-signature gene Ki67 in T cells (Fig. 7M-P). However, when CD8 expression was performed with anti-CD3 and anti-CD28 antibodies under 10 mM lactate conditions... + During T cell activation, lactate was found to reduce the expression of CD44 and Ki67 (Figure 7M-P).
[0290] In summary, lactate inhibits CD8 in the tumor microenvironment by upregulating the transcriptional activity of MondoA. + T cell activation.
[0291] Example 5: MondoA Deletion Enhanced CD8 + T-cell glycolytic metabolism and mitochondrial function
[0292] To clarify MondoA-TXNIP axis control CD8 + The molecular mechanisms of T cell function, invented by MondoA fl / fl And MondoA fl / fl CD8 isolated from Cd4-cre mice + T cell transcriptomics analysis.
[0293] Differential gene enrichment analysis (GSEA) showed that in MondoA-deficient CD8... + Enhanced glycolysis and oxidative phosphorylation metabolism in T cells (Fig. 8A, B).
[0294] Given that MondoA is an intracellular glucose sensor, CD8+ was detected using a 2-NBDG probe. + T cell glucose uptake confirms MondoA-deficient CD8 + T cells compared to wild-type CD8 + T cells have a higher glucose uptake capacity (Figure 11A).
[0295] Importantly, the inventors discovered that MondoA lacked CD8. + T cells enhance glucose uptake by promoting GLUT1 expression on the cell surface (Fig. 8C). Consistent with this, MondoA deficiency increases CD8+ expression. + T cell glycolysis (Fig. 8D and Fig. 11B, C), glucose consumption (Fig. 11D), and lactate production (Fig. 11E). Metabolic restriction attenuates tumor-invasive CD8 cells. + Metabolic adaptation and antitumor activity of T cells.
[0296] The inventors further analyzed the effect of lactic acid on CD8. +Regulation of metabolic gene networks in T cells: GSEA showed that lactate treatment reduced glycolysis and oxidative phosphorylation signaling pathways (Fig. 8E, F). Under high lactate conditions, MondoA deficiency promoted CD8... + Expression of GLUT1 on T cells (Figure 8G).
[0297] Seahorse experiments revealed that MondoA lacked CD8. + Increased oxidative phosphorylation levels in T cells (Fig. 8H and Fig. 11F, G).
[0298] The next step was to investigate whether MondoA deficiency-induced metabolic remodeling affects mitochondrial function. Flow cytometry analysis showed that MondoA deficiency enhances CD8+ mitochondrial function. + The mitochondrial membrane potential of T cells is damaged by high lactate. + Interestingly, MondoA deficiency reduces the damage of lactate to mitochondrial membrane potential in T cells (Fig. 8I,J).
[0299] In addition, lactate reduces CD8 + The number and cristae density of mitochondria in T cells (Fig. 8K-N). In contrast, MondoA-deficient CD8... + T cells have more mitochondria (Fig. 8L), and their mitochondrial cristae are more compact (Fig. 8M, N). Importantly, CD8... + MondoA deficiency in T cells can alleviate lactate-mediated reduction in mitochondrial fitness (Fig. 8K-N).
[0300] In summary, these results indicate that inhibiting the MondoA-TXNIP axis promotes CD8 + T cells promote glycolysis and oxidative phosphorylation metabolism, enhance mitochondrial function, and thus promote CD8. + T-cell anti-tumor immune response.
[0301] Example 6: SBI-477 simultaneously promotes CD8 + T cells' tumor-killing function and weakened Treg cells' immunosuppressive function.
[0302] MondoA is a glucose metabolism sensor. To investigate whether SBI-477's inhibition of MondoA transcriptional activity affects CD8... + T cell metabolism, as revealed by flow cytometry analysis, showed that SBI-477 promotes CD8 metabolism. + Glucose uptake by T cells (Fig. 10A, B).
[0303] Furthermore, the inventors discovered that MondoA deletion eliminates CD8. +The reduced expression of SBI-477-dependent TXNIP and ARRDC4 in T cells indicates that SBI-477 specifically inhibits MondoA transcriptional activity (Fig. 10C).
[0304] Considering the MondoA-TXNIP axis at CD8 + SBI-477 plays an important role in the tumor-killing function of T cells. Flow cytometry analysis revealed that SBI-477 increases CD8+ by inhibiting the transcriptional activity of MondoA. + T cell cytokine production (Fig. 10D-F).
[0305] To further analyze SBI-477's effect on CD8 + Effects on T cell function, CD8 isolated from OT-I mice + T cells, and CD8 after treatment with SBI-477. + T cells were co-cultured with MC38-OVA tumor cells for 24 hours, and the tumor cells were detected by CD8 activation. + Following T cell killing, the released lactate dehydrogenase (LDH) activity was found to be enhanced by SBI-477 on CD8. + T cell cytotoxicity (Figure 10G). Studies have reported that in the microenvironment of various cancer types, Treg cells suppress the overactivation, proliferation, and cytokine production of effector T cells (Teff), thereby disrupting the anti-tumor immune response of effector T cells, leading to tumor immune escape and poor patient prognosis. Therefore, finding a way to enhance CD8+ cytotoxicity is crucial. + This is a key factor that simultaneously weakens the immunosuppressive capacity of Treg cells while maintaining the effector function of T cells, and is of great significance for improving the efficacy of tumor immunotherapy.
[0306] To investigate whether SBI-477 targets the MondoA-TXNIP axis and impairs the inhibitory function of Treg cells, the inventors in vitro used CD4+ from human peripheral blood... + T cells were polarized into induced Treg cells, which were then treated with either a control or SBI-477. Quantitative real-time PCR results showed that SBI-477 reduced TXNIP expression in Treg cells but had no effect on MondoA levels (Figure 10H).
[0307] Importantly, the inventors discovered that SBI-477 inhibits the transcription of genes related to the repressive function of Treg cells (Figure 10I). To investigate whether MondoA regulates the interaction between Treg cells and CD8... + In vitro inhibition experiments were conducted to investigate the interactions between T cells, revealing that SBI-477 treatment enhanced the inhibition of CD8+ in Treg cells. + The inhibition of T cell proliferation was impaired (Fig. 10 J, K).
[0308] In summary, inhibition of the MondoA-TXNIP axis has a dual regulatory effect: it weakens the inhibitory function of Treg cells but enhances CD8. + The tumor-killing function of T cells.
[0309] Example 7: SBI-477 Enhanced CD8 + Anti-tumor immune response in T cells
[0310] The inventors' research results indicate that SBI-477 enhances CD8 + The effector function of T cells, to investigate whether SBI-477 affects CD8 in the tumor microenvironment. + The anti-tumor function of T cells. First, using various mouse tumor models, including MC38 colorectal cancer, B16 melanoma, and KPC1199 pancreatic cancer, the inventors found that SBI-477 significantly inhibited tumor growth and promoted anti-tumor immune responses.
[0311] In a mouse model of subcutaneous colorectal cancer xenografts, SBI-477 reduced TXNIP expression in muscle and tumor tissues (Figure 13A, B). Flow cytometry analysis also revealed that, compared with the control group, SBI-477 treatment significantly reduced CD8 expression. + TXNIP expression was significantly reduced in T cells (Fig. 12D). Interestingly, SBI-477 significantly reduced tumor growth rate and tumor weight in tumor-bearing mice (Fig. 12A-C).
[0312] The inventors further investigated the effects of SBI-477 on CD8 inhibitors in tumor infiltration. + The study investigated the effect of SBI-477 on T cell glucose uptake, showing that it significantly increased CD8 uptake compared to the control group. + T cell glucose uptake (Fig. 13C, D). More importantly, compared with the control group, SBI-477 significantly increased CD8+ infiltrating tumor cells. + T cells expressed IFN-γ and TNF-α (Fig. 12E), but there was no significant difference in the proportion of T cells and cytokine production between the spleen and lymph nodes (Fig. 13E-H). These data suggest that targeting the MondoA-TXNIP axis promotes CD8. + T cell glucose uptake, thereby enhancing CD8 cell infiltration of tumors. + Effector function of T cells.
[0313] Moreover, in tumor-infiltrating CD8+ cells in tumor-bearing mice treated with SBI-477 + The number of T cells was also significantly higher in the untreated group (Figure 12F).
[0314] Furthermore, the inventors found that SBI-477 treatment significantly inhibited tumor growth in B16 melanoma and KPC1199 pancreatic cancer subcutaneous xenograft models (Figure 12G-I and Figure 12L-N). SBI-477 significantly increased the CD8+ infiltrating activity of the tumor. + The number of T cells (Fig. 12J) and the levels of cytotoxic cytokines IFN-γ, TNF-α, and GZMB (Fig. 12K and Fig. 12O) are also relevant. These results indicate that targeting the MondoA-TXNIP axis promotes CD8 in various tumors. + T-cell anti-tumor immune responses. Therefore, the MondoA-TXNIP axis is a key metabolic checkpoint, and SBI-477 significantly enhances CD8+ by targeting the MondoA-TXNIP axis. + T-cell anti-tumor immune response.
[0315] Example 8: MondoA inhibitors synergistically enhance anti-tumor immune effects in conjunction with anti-PD-1 therapy, and MondoA inhibitors can enhance the immune response against colorectal tumors resistant to anti-PD-1 therapy.
[0316] To investigate whether the combination therapy of MondoA inhibitors and anti-PD-1 could synergistically enhance anti-tumor immunity, the inventors treated MC38 tumor-bearing mice with SBI-477 and anti-PD-1 alone or in combination, and then measured tumor size and weight. Notably, SBI-477 treatment significantly reduced tumor growth, with efficacy comparable to anti-PD-1 treatment. Importantly, the inventors found that the combination of SBI-477 and anti-PD-1 better inhibited tumor growth compared to anti-PD-1 alone (Figures 14A-D).
[0317] Next, we compared SBI-477 with PD-1-targeted immune checkpoint therapy and the combination of SBI-477 and anti-PD-1 for tumor-invasive CD8 inhibitors. + Effects on T cell function. Consistently, both SBI-477 and anti-PD-1 treatment increased tumor-invasive CD8+. + The production of effector cytokines in T cells, and the presence of CD8+ in tumor-infiltrating cells in the combination therapy group. + T cells secrete more cytokines. (Fig. 14E, F).
[0318] In the treatment of various cancers, a significant proportion of patients do not benefit from anti-PD-1 therapy due to primary and acquired resistance during the treatment process. This example investigates the tumor-invasive CD8+ in a colorectal cancer model resistant to anti-PD-1 therapy.+ Replacement therapy for T-cell function.
[0319] To further evaluate whether SBI-477 could inhibit the progression of tumor resistance to immune checkpoint anti-PD-1 therapy, the inventors used an anti-PD-1 resistant colorectal cancer model (MC38R). Wild-type mice inoculated with MC38R cells were divided into three groups, treated with control, anti-PD-1, and SBI-477, respectively. SBI-477 significantly inhibited the growth of MC38R tumors, while anti-PD-1 had no effect (Figure 14G-I).
[0320] Furthermore, the inventors discovered that SBI-477 treatment can enhance the invasive CD8+ of MC38R tumors. + T cell cytokine production, while anti-PD-1 treatment does not affect tumor-invasive CD8 cells. + T cell cytokine secretion (Fig. 14J-L). Therefore, inhibiting MondoA via SBI-477 can act as a mechanism to activate tumor-invasive CD8 cells. + T-cell replacement therapy.
[0321] These results indicate that targeting the MondoA-TXNIP axis can synergize with anti-PD-1 and enhance the immune response against anti-PD-1 resistant colorectal tumors, representing a novel intervention strategy for colorectal cancer cells resistant to anti-PD-1 therapy. In conclusion, targeting the MondoA-TXNIP axis with the inhibitor SBI-477 can enhance the anti-tumor immune response and provide a novel alternative strategy for colorectal cancer patients with limited response to anti-PD-1 therapy.
[0322] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention. Therefore, the scope of protection of this patent should be determined by the appended claims.
Claims
1. Downregulation of the MondoA-TXNIP axis in the preparation of enhanced CD8 molecules + Use in formulations that induce T-cell killing.
2. The use as described in claim 1, characterized in that, The downregulated molecules include those selected from: MondoA downregulated molecules, TXNIP downregulated molecules, and downregulated molecules that interact with MondoA and TXNIP.
3. The use as described in claim 2, characterized in that, The MondoA downregulating molecules include: reagents that knock out, knock down, or silence the MondoA gene or the TXNIP gene, and reagents that inhibit the activity of the MondoA protein or the TXNIP protein.
4. The use as described in claim 2, characterized in that, The MondoA downregulating molecules include: small molecule compounds that specifically inhibit the activity of MondoA or TXNIP proteins; CRISPR gene editing reagents, homologous recombination reagents, or site-directed mutagenesis reagents targeting the MondoA or TXNIP genes, wherein the reagents induce loss-of-function mutations in the MondoA or TXNIP genes; and interfering molecules that specifically interfere with the expression of the MondoA or TXNIP genes. More preferably, the small molecule compounds that specifically inhibit MondoA proteins include SBI-477.
5. The use as described in claim 2, characterized in that, The downregulated molecules of the MondoA-TXNIP interaction include reagents that weaken the binding of MondoA to the TXNIP gene promoter.
6. The use as described in claim 1, characterized in that, The enhanced CD8 + T-cell killing effects include: Suppressing tumors; preferably, the tumors include tumors resistant to immune checkpoint inhibitors; Inhibit pathogens, such as viruses or bacteria; Enhanced CD8 + T cell cytotoxicity; Promote CD8 + T cells produce cytokines; preferably, the cytokines include: IFN-γ, TNF-α, GZMB, and Perforin.
7. The use as described in claim 6, characterized in that, The tumors include: colorectal cancer, pancreatic cancer, melanoma; or The immune checkpoint inhibitors include: anti-PD-1, anti-PD-L1, or anti-CTLA4.
8. The purpose of the Mondo A-TXNIP axis is to filter and enhance CD8. + Substances that induce T-cell killing.
9. A screening enhancement CD8 + Methods involving substances that induce T-cell killing include: (1) Contact the candidate material with a system containing the MondoA-TXNIP axis; (2) Select substances that downregulate the MondoA-TXNIP axis; these substances are those that enhance CD8. + Substances useful for T-cell killing; wherein, the downregulation includes: downregulating MondoA, downregulating TXNIP, or downregulating the interaction between MondoA and TXNIP.
10. The method as described in claim 9, characterized in that, Step (1) includes: adding candidate material to the system containing the MondoA-TXNIP axis; Step (2) includes: detecting changes in each protein or its encoding gene in the MondoA-TXNIP axis and comparing it with a control group, wherein the control group is a system containing the MondoA-TXNIP axis without the candidate substance added; if the candidate substance downregulates MondoA, downregulates TXNIP, or downregulates the interaction between MondoA and TXNIP, then the candidate substance is effective in enhancing CD8. + Substances useful for T-cell killing.
11. A modified CD8 + T cells with enhanced killing activity, wherein an exogenous MondoA-TXNIP axis down-regulating molecule is introduced, or the cells are treated with an exogenous MondoA-TXNIP axis down-regulating molecule; the down-regulating molecule includes those selected from: MondoA down-regulating molecules, TXNIP down-regulating molecules, and down-regulating molecules of MondoA and TXNIP interaction; the down-regulating molecule is the down-regulating molecule as defined in claim 2; preferably, the killing activity is tumor killing activity.
12. The modified CD8 according to claim 8 + The application of T cells is used to prepare agents or kits for inhibiting tumors or pathogens; preferably, the tumors include tumors resistant to immune checkpoint inhibitors.
13. The modified CD8 according to claim 12 + The application of T cells is characterized by... The tumors include colorectal cancer, pancreatic cancer, and melanoma; preferably, the immune checkpoint inhibitors include anti-PD-1, anti-PD-L1, or anti-CTLA4.
14. An enhanced CD8 + Preparations or kits containing T-cell killing / tumor-inhibiting or pathogen-inhibiting agents, wherein the preparation comprises an effective amount of a MondoA-TXNIP axis downregulating molecule and an immune checkpoint inhibitor.
15. The medicine box as described in claim 14, characterized in that, The downregulated molecules include those selected from: MondoA downregulated molecules, TXNIP downregulated molecules, and downregulated molecules that interact with MondoA and TXNIP, such as the small molecule compound SBI-477, which specifically inhibits MondoA activity; or The immune checkpoint inhibitors include: anti-PD-1, anti-PD-L1, or anti-CTLA4.
